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ABSTRACT
Recent outbreaks in vertically transmitted viruses, such as Zika virus and HIV,
has rejuvenated interest in fetal and neonatal immune tolerance. Babies are susceptible
to vertically transmitted viruses because fetal and neonatal immune systems are
considered to be immune privileged and will tolerate antigens presented to them by their
mother. Thus, understanding the mechanisms of this tolerance is important to design
effective treatments for infected mothers to protect their offspring. Here, I define a novel
Treg, a type of T cell that mediates tolerance, named bidirectional T cells (BiT), found in
human umbilical cord blood (UCB). These cells are induced by monocytes that provide
transforming growth factor beta (TGF-β), a necessary molecule for Treg induction. BiT
express classical Treg markers, such as Foxp3 and CD25, but also produce
proinflammatory cytokines such as GM-CSF and IL-8. This profile suggests that BiT are
capable of suppressing and activating the immune system. These differences suggest
that BiTs may function differently from in vitro induced Tregs (iTregs), peripheral in vivo
induced Tregs (pTregs) and thymus derived Tregs (tTregs).
Our lab has been able to show that physiological levels of calcitriol, the active
form of vitamin D, is able to upregulate the induction of BiT. Furthermore, we also
discovered that calcitriol upregulates NRP-1, a receptor and activator of TGF-β, on
monocytes. We decided to further determine the effect of calcitriol on T cells and
monocytes to better understand its role in the immune suppression. We found that
x

calcitriol promoted expression of molecules that turn off the immune system,
CTLA-4 and PD-L1, on T cells. The NRP-1 expression on these monocytes was
upregulated, which lead to increased migration of cells. The migration towards VEGF
signifies what happens after tissue damage or during the growth of new blood vessels.
In summary, we describe a novel Treg (BiT), and found that calcitriol promoted immune
suppression by upregulating BiT, molecules that turn off the immune system, and IFN-β
impeded the migration of cells to areas that require growth.

xi

CHAPTER ONE: REVIEW OF THE LITERATURE
T Cell Subsets
T lymphocytes, or T cells, develop in the thymus and play key roles in adaptive
immunological responses. T cells are activated through the stimulation of their T cell
receptor (TCR) with peptide presented on a major histocompatibility complex (MHC),
along with co-stimulation of CD28 by binding with CD80 or CD86 (Bjorkman et al., 1987;
Haskins et al., 1983; Jenkins, Ashwell, & Schwartz, 1988; Lenschow et al., 1994;
Madrenas, Chau, Smith, Bluestone, & Germain, 1997; Mueller, Jenkins, & Schwartz,
1989). Further, cytokines aid in stimulation and directing the function and differentiation
of these T cells. There are two main lineages of T cells, defined by the composition of
their TCR: αβ (alpha beta) and γδ (gamma delta) (Brenner et al., 1987; Meuer et al.,
1983). The primary focus of this research is on αβ T cells, which divide into two
subtypes, CD4 T cells and CD8 T cells. CD4 and CD8 are T cell co-receptors, which aid
in TCR stimulation. They bind MHC class II (MHC II) and MHC class I (MHC I),
respectively (Bjorkman et al., 1987; Madrenas et al., 1997). CD8 T cells are also known
as cytotoxic T cells because upon activation they release perforin and granzymes,
which lead to apoptosis of neighboring cells (Kisielow et al., 1975; Krähenbühl et al.,
1988; Peters et al., 1991). On the other hand, CD4 T cells, also known as helper T cells,
have multiple subsets.
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CD4 T Helper Subsets and their Functions
CD4 T helper (Th) cells are divided into seven different subsets. Each subset is
defined by the cytokines they produce and at least one key upregulated transcription
factor. The existence of two distinct subtypes of CD4 T cells, Th1 and Th2 cells, were
discovered in 1986 (Mosmann, Cherwinski, Bond, Giedlin, & Coffman, 1986). This study
found T cell clones split into two distinct groups that produced different cytokine profiles
upon stimulation, where Th1 produced IL-2 and IFN-γ while Th2 produced BSF-1, now
known as IL-4 (Hsieh et al., 1993; Le Gros, Ben-Sasson, Seder, Finkelman, & Paul,
1990; Mosmann et al., 1986; Swain, Weinberg, English, & Huston, 1990). In the
following years, the search began to find what factors lead to the clonal diversity of T
cells. IL-12 was not discovered until 3 years after the discovery of Th1 cells, and it took
until 1993 to discover that Th1 cells are induced by IL-12 (Hsieh et al., 1993; Kobayashi
et al., 1989). Since IL-4 was already a known factor, the discovery that Th2 cells are
induced by IL-4 came within four years of their initial discovery (Hsieh et al., 1993; Le
Gros et al., 1990; Mosmann et al., 1986; Romagnani, 1999; Swain et al., 1990). At the
time, reagents did not exist to determine which other factors were produced by Th1 and
Th2 cells. However, it is now known that Th1 cells express the transcription factor T-bet
and produce IFN-γ and TNF-α, while Th2 cells express GATA3 and produce IL-4, IL-5,
IL-10, and IL-13 (Romagnani, 1999; Szabo et al., 2000; W. Zheng & Flavell, 1997). Th1
cells generate immune responses against infection caused by intracellular parasites,
like bacteria and viruses. In contrast, Th2 cells are more prevalent in allergic responses,
stimulate B cells to produce antibodies, and provide protection against helminths and
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extracellular parasites (Mosmann et al., 1986; Romagnani, 1999).
Another more recently discovered Th subset is Th9. These cells express the
transcription factors GATA-3 and IRF4, produce IL-9, are induced by the presence of IL4, and also play a role in allergic response like Th2 cells, but also play a role in tissue
inflammation (Dardalhon et al., 2008; Schmitt et al., 1994). However, in addition to IL-4,
transforming growth factor-beta (TGF-β) is also necessary to induce these cells and for
the expression of the transcription factors IRF-4 and FoxO1 (Dardalhon et al., 2008;
Schmitt et al., 1994; Staudt et al., 2010; Veldhoen et al., 2008). The necessity and
function of these cells outside of allergic disease are still under scrutiny, due to
conflicting experimental results and since other cell types can produce IL-9 (Kaplan,
2013).
Three Th subsets all require the presence of IL-6 for their differentiation. These
are Th22, Tfh, and Th17. Th22 is similar to Th9 and Th2 in the sense that these cells
also play a role in allergic responses and tissue inflammation, but they express the aryl
hydrocarbon receptor (AhR) as a key transcription factor and require TNF-α in addition
to IL-6 for induction (Duhen, Geiger, Jarrossay, Lanzavecchia, & Sallusto, 2009; Trifari,
Kaplan, Tran, Crellin, & Spits, 2009). These cells produce IL-22, TNF-α, and IL-13
(Duhen et al., 2009; Trifari et al., 2009). T follicular helper cells (Tfh) are located in
germinal centers due to CXCR5 expression where they perform B cell help (Breitfeld et
al., 2000; C. H. Kim et al., 2001; Schaerli et al., 2000). IL-6 and IL-21 are necessary for
T cells to differentiate into Tfh and this leads to the upregulation of the transcription
factor BCL-6 and subsequent production of IL-21, which further aids in germinal center
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formation and B cell help (Bauquet et al., 2009; Chtanova et al., 2004; Eto et al., 2011;
Johnston et al., 2009; Linterman et al., 2010; R. I. Nurieva et al., 2008; R. I. Nurieva et
al., 2009; Vogelzang et al., 2008). The final subset that requires IL-6 for induction is
Th17 (Zhou et al., 2007). These cells also require TGF-β and their dominant
transcription factor is RORγT (Annunziato et al., 2007; Mangan et al., 2006; R. Nurieva
et al., 2007). These cells play a role in tissue inflammation, autoimmunity, and
clearance of extracellular pathogens (Annunziato et al., 2007; Langrish et al., 2005).
They do this through the production of IL-17 and IL-22 (Annunziato et al., 2007; S. C.
Liang et al., 2006; R. Nurieva et al., 2007; Yao et al., 1995).
The final type of Th cell are T regulatory cells (Tregs). Tregs only require the
presence of TGF-β and IL-2 which then induces the transcription factor Foxp3, which is
necessary for suppression (Bettelli et al., 2006; Fontenot, Gavin, & Rudensky, 2003; S.
Fu et al., 2004; S. G. Zheng, Wang, Wang, Gray, & Horwitz, 2007). In fact, TGF-β
signaling is necessary for Foxp3 transcription. Mice deficient in TGF-β1 develop a lethal
lymphoproliferative autoimmune syndrome (Shull et al. 1992). These cells are unique in
the fact that they suppress immune responses and promote immunological tolerance
rather than promote inflammation or clearance of pathogens (Fontenot et al., 2003;
Sakaguchi, Sakaguchi, Asano, Itoh, & Toda, 1995). These cells can further produce IL10 and TGF-β, leading to more immune suppression (Asseman, Fowler, & Powrie,
2000). Lastly, these cells are also necessary for immunological tolerance, which is when
cells determine if an antigen is self or non-self (Asseman et al., 2000; Sakaguchi et al.,
1995). This dissertation focuses primarily on immune suppression and Tregs.
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T Regulatory Cell Subsets
There are four main types of Tregs: tTregs, pTreg, iTreg, and Tr1 (Abbas et al.,
2013). The first type of Treg to be defined were thymic Tregs (tTregs). Thymectomy and
non-lethal irradiation were found to precede the development of autoimmune disease
(Nishizuka & Sakakura, 1969; Penhale, Farmer, McKenna, & Irvine, 1973). This
suggested that the thymus produces a suppressive cell. A few years later, studies
showed that adding back total thymocytes or specifically CD4+CD8- from the thymus
could prevent the onset of autoimmunity in thymectomized mice, suggesting the thymus
gives rise to an immunosuppressive CD4+ T cell (Penhale et al., 1973; Sakaguchi,
Takahashi, & Nishizuka, 1982). This finding suggested that Tregs are naturally
generated in the thymus, and thus these Tregs were termed thymic Tregs (tTregs) (Itoh
et al., 1999). Peripheral Tregs (pTregs) develop from naïve CD4 T cells in the periphery,
rather than the thymus (Curotto de Lafaille, Lino, Kutchukhidze, & Lafaille, 2004;
Kretschmer et al., 2005). To better understand Treg biology and in an effort to
understand how to culture Tregs for therapeutic use, researchers sought to understand
how to induce Tregs in a laboratory setting. Naïve CD4 T cells in vitro TCR stimulated in
combination with recombinant TGF-β and IL-2 induces Tregs that can suppress to the
same capacity as tTregs and pTregs both in vitro and in vivo (W. Chen et al., 2003;
Davidson, DiPaolo, Andersson, & Shevach, 2007; Fantini et al., 2004; S. G. Zheng et
al., 2007). The final type of Treg are type 1 Tregs (Tr1). These are induced in the
periphery via IL-10 and produce high levels of IL-10 in comparison to other Treg
subtypes (Gagliani et al., 2013; Groux et al., 1997). This Treg subtype is unique in the
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fact that it does not express Foxp3, the key suppressive transcription factor of other
Treg subtypes. Tr1 also has unique markers, CD49b and Lag-3 on their surface to
distinguish them from other Treg subtypes which makes them easier to study (Gagliani
et al., 2013; Zeng, Zhang, Jin, & Chen, 2015).
For years, the field has attempted to find differences in surface marker and
transcription factor expression to distinguish tTreg, pTreg, and iTreg subsets from each
other. The first marker to be discovered for Tregs was CD25. Suppressive cells from
thymocytes were found to express CD5 and low levels of CD45B, so the hunt was on to
find a specific marker for this subset. This study uncovered the IL-2 receptor alpha
chain, CD25. From here, the authors adoptively transferred CD25 depleted
spleenocytes to T cell-deficient recipients. The recipients that received CD25 depleted
cells, but not those that received total spleenocytes, suffered from severe autoimmunity.
In contrast, co-transfer of enriched CD4+CD25+ T cells prevented the development of
autoimmunity, definitively demonstrating that CD4+CD25+ cells are immunosuppressive
and required for immune homeostasis (Sakaguchi et al., 1995). Now, it is known that all
three types express CTLA-4, GITR, PD-1, and CD25 (Curotto de Lafaille et al., 2004;
Shevach & Thornton, 2014). There have been suggestions that the transcription factor
Helios and a secondary TGF-β receptor, neuropilin-1 (NRP-1), distinguish tTregs from
other Treg subtypes (Curotto de Lafaille et al., 2004; X. Lin et al., 2013; Shevach &
Thornton, 2014). However, in humans, NRP-1 is no longer considered a marker for
Tregs and Helios can be expressed in other Treg subsets (Milpied et al., 2009).
The expression of the master transcription factor Foxp3 is shared among tTregs,
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pTregs, and iTregs. In 2003, three groups defined this transcription factor as the
functional driver of suppression in Tregs (Fontenot et al., 2003; Hori, Nomura, &
Sakaguchi, 2003; Khattri, Cox, Yasayko, & Ramsdell, 2003). These groups found that
mice without the presence of Foxp3, also known as scurfy mice, succumb to severe
lymphoproliferative diseases and autoimmunity (Fontenot et al., 2003; Khattri et al.,
2003). Scurfy mice have a missense mutation in foxp3, however it was discovered that
addition of CD4+CD25+Foxp3+ T cells or retroviral foxp3 gene transfer into these mice
rescued them from disease (Fontenot et al., 2003; Hori et al., 2003). A follow-up study
using a CD4 specific knockout of Foxp3 was sufficient to induce autoimmunity (Fontenot
et al., 2005). In humans, immunodysregulation polyendocrinopathy enteropathy X-linked
(IPEX) syndrome occurs when Foxp3 is mutated (Bennett et al., 2001). This disease
leads to rapid formation of autoimmunity, and if not treated (typically with a bone
marrow transplant), the patient will die (Bennett et al., 2001). From these studies, Foxp3
is essential and non-redundant for stabilizing the CD4+CD25+ Treg lineage and
controlling Treg development and function (Gavin et al. 2007; Fontenot et al. 2003).
While tTregs, pTregs, and iTregs express Foxp3 in order to be functionally
suppressive, there is evidence that Foxp3 is differentially regulated on the epigenetic
level via variances in methylation (Kitagawa, Ohkura, & Sakaguchi, 2013; Lal et al.,
2009; Morikawa et al., 2014). These variances are still the only true marker to
distinguish between different Treg subsets (Minskaia et al., 2018). Epigenetic regulation
by methylation occurs at the 5’-cytosine of CpG dinucleotides (Morikawa et al., 2014).
Accessible CpG dinucleotides are called CpG islands, and methylation at these sites
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leads to downregulation of transcription by preventing binding of transcription factors
near these sites (Kitagawa et al., 2013; Minskaia et al., 2018). Foxp3 has three
conserved non-coding sequences (CNSs) (Y. Zheng et al., 2010). Induction of Foxp3 is
controlled by TGF-β signaling activating the transcription factor Smad3. Smad3 binds to
the Foxp3 locus on the CNS1 region where it positively regulates the transcription of
Foxp3 (Tone et al. 2008). tTregs are defined as having DNA hypomethylation on Foxp3
CNS2 (Morikawa et al., 2014; Someya et al., 2017; Y. Zheng et al., 2010). The CNS2
aids in stability of Foxp3 expression (Someya et al., 2017; Y. Zheng et al., 2010). In
contrast, iTregs and pTregs have increased CNS2 methylation, and rather
demethylation of CNS1 (Y. Zheng et al., 2010). CNS1 aids in iTreg and pTreg
generation, while CNS3 controls Foxp3 expression in precursor T cells (Y. Zheng et al.,
2010). CNS1 is dispensable for tTreg induction, however T cells from mice lacking
CNS1 were unable to generate pTregs/iTregs and instead had excessive Th2 mediated
inflammation. This demonstrated the importance of the CNS1 region for the generation
of pTregs and iTregs (Josefowicz et al., 2012). In mice, Foxp3 is expressed only by T
cells with regulatory function. However, in humans, Foxp3 is transiently expressed in all
activated T cells, but is only stably maintained in Tregs due to hypomethylation of CNS2
(Gavin et al., 2006).
Taken together, there are multiple important Treg subsets in humans that are
functionally suppressive. All but one subset express Foxp3, and the epigenetic
regulation of Foxp3 is different depending on the type of Treg. However, besides this
methylation, it is not well understood what the genetic differences are between different
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types of Tregs and what markers can be used to distinguish between them.
Immune Checkpoint Molecule Expression and Regulation
The immune system has natural mechanisms besides Tregs to regulate T cell
responses, which are referred to as checkpoint molecules (Chikuma, 2017). Cytotoxic
T-lymphocyte associated antigen 4 (CTLA-4) inhibits T cell co-stimulation, and thus,
inhibits activation of T cells, because it has a roughly 10X higher affinity than CD28 to
bind co-stimulatory molecules CD80 and CD86 (Krummel & Allison, 1995; Linsley et al.,
1994; van der Merwe, Bodian, Daenke, Linsley, & Davis, 1997; Walunas et al., 1994).
CTLA-4 was later reported to have both cell-intrinsic and cell-extrinsic effects (Jain,
Nguyen, Chambers, & Kang, 2010). This means that while cells that express CTLA-4
undergo anergy after contact with CD80 or CD86 (intrinsic) it has also been observed
that these cells are able to extrinsically suppress neighboring cells (Jain et al., 2010;
Wang et al., 2012). CTLA-4 was discovered when mice lacking it had T cells with high
reactivity to self-tissues, uncontrolled proliferation, and died due to tissue infiltration
within three weeks (Brunet et al., 1987; Waterhouse et al., 1995). Due to the loss of
CTLA-4 and Foxp3 leading to similar phenotypes, there was an interest in studying
whether these genes were part of a common pathway (Walker, 2013). However, it was
found that they were not regulated in the same pathway, since mice lacking one would
have an increase of the other (Walker, 2013). But there is supporting evidence that
while Tregs lacking CTLA-4 can be suppressive, their suppressive function is enhanced
when they co-express Foxp3 and CTLA-4 (Walker, 2013). More studies need to be
further conducted on this topic because study and method variations have led to a

10
plethora of conflicting results on the importance and function of CTLA-4 on Tregs.
Another key checkpoint molecule is programmed death-1 (PD-1) (Ishida, Agata,
Shibahara, & Honjo, 1992). This receptor binds to programmed death ligand-1 and -2
(PD-L1 and PD-L2, respectively) on B, T, myeloid, and dendritic cells. Activation of this
signaling pathway leads to anergy or cell death of cells expressing PD-1 (Dermani,
Samadi, Rahmani, Kohlan, & Najafi, 2019). Similar to CTLA-4, there is evidence of the
PD-1/PD-L1 axis having a functional effect on Tregs. In an umbilical cord blood study, it
was found that using monoclonal antibodies to block PD-1/PD-L1 signaling resulted in a
significant reduction in the Foxp3+ T cell population, suggesting a role in Treg induction
(de Roock et al., 2011). In agreement with this, in an APC PDL1-/- model, these mice
were unable to generate pTregs, further demonstrating an important role in PD-1/PD-L1
signaling in Treg induction (Francisco et al., 2009). This study continued further to
demonstrate that PD-L1 is able to enhance Foxp3 expression due to inhibiting the
Akt/mTOR signaling cascades, which is known to inhibit Treg induction (Francisco et al.,
2009).
For T cells, PD-1 expression is induced upon TCR stimulation (Chikuma et al.,
2009). This expression is upregulated on activated T cells but reduces over time in the
absence of TCR stimulation (Chikuma et al., 2009; S. Simon & Labarriere, 2017;
Youngblood et al., 2011). PD-1 is considered to be the first marker of T cell activation,
which is induced within 24 hours of initial antigen exposure (Chikuma et al., 2009).
Mutation of the NFAT binding sight in the PD-1 promoter led to loss of promoter activity,
suggesting the transcription factor NFAT directly regulates PD-1 transcription; NFAT is
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downstream of TCR and calcium signaling events (Oestreich, Yoon, Ahmed, & Boss,
2008). In contrast to its receptor, PD-L1 is expressed constitutively on T cells and is
further upregulated after TCR stimulation (Sharpe, Wherry, Ahmed, & Freeman, 2007).
PD-L1 expression is also regulated by multiple pathways and factors, such as hypoxia,
epigenetic modifications, AP-1, and tumor suppressors (Shen et al., 2019; Sun,
Mezzadra, & Schumacher, 2018).
Similar to PD-1, CTLA-4 is not expressed on the surface of resting or naive T
cells but is induced after TCR stimulation (Lindsten et al., 1993). When CTLA-4 is not
on the surface of T cells, it is often found stored in lysosomes, endosomes, or
intracellular vesicles in memory T cells (Iida et al., 2000; Linsley et al., 1996).
Intracellular calcium has been found to promote CTLA-4 surface expression and after
TCR stimulation cell surface CTLA-4 was found to localize towards the site of activation
(Linsley et al., 1996). It was later found that lysosomal vesicles release their stores of
CTLA-4 in memory T cells towards the surface of cells allowing for increased
expression post-activation (Iida et al., 2000). However, CTLA-4 expression is not
upregulated on the surface of naïve T cells until after 48-72 hours, and the peak in
mRNA expression occurs between 24-48 hours post-activation (Jago, Yates, Câmara,
Lechler, & Lombardi, 2004; Krummel & Allison, 1995; Lindsten et al., 1993; Linsley et
al., 1992; Metzler, Burkhart, & Wraith, 1999; Walunas et al., 1994). CTLA-4 is regulated
by rapid membrane recycling via the clathrin-dependent internalization pathway by
binding to AP-2 via a YVKM motif ((Bradshaw et al., 1997; Chuang et al., 1997;
Nakaseko et al., 1999; Perkins et al., 1996; Schneider & Rudd, 2014; Shiratori et al.,
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1997; Y. Zhang & Allison, 1997). This pathway allows for either recycling or degradation
of CTLA-4 in lysosomes which allows for control of total CTLA-4 levels (Chuang et al.,
1997; Iida et al., 2000; Shiratori et al., 1997). Akin to PD-1, NFAT has also found to play
a role in positively regulating CTLA-4 specifically in Tregs and CD4 T cells, rather than
CD8 T cells (Chan et al., 2014; Gibson et al., 2007; Takahashi et al., 2000; Y. Wu et al.,
2006). Taken together, understanding the regulation and expression of these molecules
is important for determining the suppressive capability of the cells expressing them.
Fetal/Neonatal Tolerance versus Adult Immune Tolerance
The Discovery of Fetal Tolerance
Immunological tolerance is the state of unresponsiveness towards an antigen.
Tolerance allows for the immune system to not attack “self” or host antigens. It is
important to understand the mechanisms of tolerance, as failure of tolerance to host
tissues can result in autoimmunity and tolerance to foreign antigens varies from person
to person. Fetal tolerance was first discovered in 1945 by Ray D. Owen (Owen, 1945).
In his study, he found that blood flow shared in the fetus between dizygotic cattle twins
results in exchange of blood cells and hematopoietic cells in utero. As these calves
grew into adulthood, they maintained blood cells from their twin. In fact, Owen found
that twins from different bulls (fathers) also had identical blood patterns (Owen, 1945).
In response to this study, Medawar and colleagues tested the extent of tolerance from
these mosaic cattle (Anderson, Billingham, Lampkin, & Medawar, 1951). Allogeneic skin
grafts were known to be rejected in humans and rabbits due to robust immune
responses to non-self-tissues (Anderson et al., 1951). However, they found that
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dizygotic twins, regardless of gender, did not reject the skin grafts from each other
(Anderson et al., 1951; Holick et al., 1980). Two years later, a follow-up study in mice
was performed. In this experiment, they demonstrated that CBA mice (strain A) injected
in utero with homogenized tissues from a second strain of mice (strain B) did not reject
a skin graft from strain B eight weeks post-birth (Billingham, Brent, & Medawar, 1953).
However, strain A mice still had the ability to reject the skin graft from a third, unrelated
strain of mice (strain C) (Billingham et al., 1953). The observations from these three
seminal studies demonstrated that exposure to foreign antigens in utero generate longterm antigen-specific tolerance.
While these experiments demonstrated that fetal tolerance exists, the
mechanism for how it is established is still not well understood. In recent years, studies
have found that fetuses generate Tregs that promote tolerance to in utero exposed
antigens. Umbilical cord blood (UCB) studies and pre-mature birth studies have
demonstrated an increased percentage of Tregs in comparison to adults (Dirix,
Vermeulen, & Mascart, 2013; Takahata et al., 2004). While the basal percentage of
Tregs in UCB is not different from adult blood, we and others have described that UCB
has a higher propensity to expand and differentiate into Tregs (C. C. Chang et al., 2005;
de Roock et al., 2011; J. Lee et al., 2020; Torelli et al., 2012). In agreement with
discoveries made by Owens, Billingham, and Medawar, human fetuses encounter
maternal DNA that crosses the placental barrier. Studies have found that tolerance to
these antigens persists into adulthood and promotes tolerogenic Tregs in utero
(Maloney et al., 1999; Mold et al., 2008). These data suggest that fetal tolerance is in
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part due to an environment that leads to a higher propensity for Treg induction. These
Tregs aid both in establishing self-tolerance and tolerance to maternal allo-antigens.
More needs to be done to understand why there are more Tregs in UCB and if there are
any genetic differences between these Tregs and those found in adults.
Tolerance and Aging
Above, I explain the history of fetal tolerance and how tolerance in early life can
impact patterns in lifelong tolerance. However, in this section, it is important to discuss
the differences in tolerance and Tregs as humans age. As neonates, T cells have a
higher propensity to develop into Tregs to promote tolerance to self and maternal
antigens. pTregs make up 3% of the total CD4+ repertoire at birth, in which they have
been found to persist in the body for an extended period of time where they assist in
promoting tolerance and an anti-inflammatory immune environment (Burlingham et al.,
1998; Mackroth et al., 2011; A. K. Simon, Hollander, & McMichael, 2015; Takahata et
al., 2004). As the adaptive immune system develops after birth in response to antigen
stimulation and exposure to their own gut microbiota, Treg cell numbers decline while
other Th subsets increase to match the proportion of naïve T cells (Arismendi, Kallás,
Santos, Carneiro-Sampaio, & Kayser, 2012; Santner-Nanan et al., 2008; Shearer et al.,
2003). This change is rather rapid, where evidence shows that cord blood, peripheral
blood post-birth, 1 week, 4 weeks, and 12 weeks post-birth all have unique
immunological signatures; in fact, the Treg population falls drastically in the first 36
months of age (Olin et al., 2018; Shearer et al., 2003; Zhao et al., 2007).
As humans age, there is a reduction in the function and size of the thymus, this
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process is known as thymic involution (Boehm & Swann, 2013). The thymus is largest
at birth through the first five years of life and then atrophy begins. This results in a
decline in thymopoeisis, the production of T cells, for both Tregs and naïve T cells
emigrating from the thymus. Thiault and colleagues sought to determine whether Tregs
or other T cell populations were more affected by thymic involution and observed that
kinetics of reduction in Treg versus conventional T cells (Tconv) are different (Thiault et
al., 2015). Treg emigration declines at a significantly faster rate than Tconv (Thiault et
al., 2015). The field now hypothesizes that with age, Tregs display an effector/memory
phenotype and circulate back to the thymus where they then compete for available IL-2,
thus inhibiting the production of more Tregs while allowing for continued production of
Tconv cells (Arismendi et al., 2012; Darrigues, van Meerwijk, & Romagnoli, 2018;
Santner-Nanan et al., 2008; Thiault et al., 2015). The reduction in the pTreg repertoire
has also been reported in the elderly (Darrigues et al., 2018; Jagger, Shimojima,
Goronzy, & Weyand, 2014). This decline in the Treg population and function has been a
suggested cause for the increase in prevalence of autoimmunity, inflammation, and
infection in the elderly, along with a reduction in naïve T cell population leading to a
decreased repertoire that can be primed against new antigens (Elyahu et al., 2019;
Fessler, Ficjan, Duftner, & Dejaco, 2013; Fujimaki et al., 2008; Jagger et al., 2014;
Santner-Nanan et al., 2008). These examples demonstrate a stark difference between
the available Treg populations in adolescence and adulthood in comparison to fetal and
neonatal stages. However, it is not well understood at the gene level if there are
differences in the Treg repertoires at different age points.
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Organ Development and Immune/Inflammatory Response
Effect of Infections and Inflammation on Organ Development
Fetal/neonatal tolerance is essential for survival. TORCH infections (Toxoplasma
gondii, other (such as HIV, Listeria monocytogenes, and parvovirus), Rubella,
Cytomegalovirus (CMV), and Herpesviruses (HSV)) demonstrate when tolerance is
overcome and inflammation occurs to combat the infection (Arora, Sadovsky, Dermody,
& Coyne, 2017). TORCH infections are infections capable of breaking the maternalplacental barrier that activate an immune response that can lead to abnormal placental
development, miscarriages, fetal demise, neural tube defects, abnormal brain
development, pre-term labor, and abnormal lung development (Arora et al., 2017;
Yockey & Iwasaki, 2018). Varying immune responses can activate based on the type of
the infection, leading to the production of cytokines which cause different birth
complications (Yockey & Iwasaki, 2018).
The organ most often impacted by infections during development is the brain
(Cordeiro, Tsimis, & Burd, 2015; Phillips et al., 2016; Silasi et al., 2015; Yockey &
Iwasaki, 2018; Yockey et al., 2018). Neurulation begins three weeks into gestation and
brain development continues through the first five months of gestation. After that,
myelination begins and continues into adulthood. There have been numerous studies
demonstrating that viral, bacterial, and fungal infections during pregnancy lead to brain
deformities, seizures, psychiatric disorders (such as bipolar disorder and
schizophrenia), neurodevelopmental delays, autism, cognitive impairment, and mental
retardation (Cordeiro et al., 2015; Phillips et al., 2016; Silasi et al., 2015; Yockey et al.,
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2018). Currently, there are no treatments or preventative measures against these
infections.
Of interest, viral vertical transmission is detrimental to the developing fetus. Viral
infections cause an upregulation in inflammatory cytokine expression of IL-6, TNF-α, IL1β, IFN-γ, and IFN-α/β (Yockey & Iwasaki, 2018). Mouse and rat studies have
demonstrated that in utero parvovirus infection leads to a 90-fold increase of IFN-β
expression; trophoblast cells respond to type 1 IFNs by producing IFN-stimulated genes
which results in impaired differentiation, reduced developmental capacity, and fetal
growth (Baines et al., 2020; Rostovsky & Davis, 2015). Furthermore, it was found that
type 1 interferons (IFN-α/β) were responsible for growth restriction, microcephaly,
spontaneous abortions, and fetal demise after Zika virus infection (Yockey et al., 2018).
Supporting the evidence of IFN-β negatively affecting fetal and placental sufficiency, a
case study of a woman taking IFN-β to control her multiple sclerosis (MS) during her
pregnancy lead to severe fetal growth restriction, pre-term birth, respiratory distress,
and severe pre-eclampsia (Salahudheen & Begam, 2016). Neural stem cells are
capable of responding to viral infection and are a known source of IFN-β (J. Y. Lin, Kuo,
& Huang, 2019). Taken together, these studies highlight that the anti-viral immune
response is detrimental to fetus development. However, the IFN anti-viral response is
important for combating infection, and without the IFN response against the virus there
is increased maternal and fetal disease severity (Racicot et al., 2017). These infections
highlight the need for a better understanding of how infections are able to cross the
maternal-placental barrier and how to develop vaccinations that work against them in
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utero, so the immune system does not activate and lead to detrimental health
outcomes.
Besides the direct effects on the inhibition of fetal development, IFN-β is also a
potent inhibitor of angiogenesis, the sprouting of new blood vessels. Type I IFNs are
produced by multiple tissues upon viral and bacterial infections and play essential roles
in eliciting an anti-viral and anti-microbial immune response (Perry, Chen, Zheng, Tang,
& Cheng, 2005). IFN-β, a type I IFN, has previously been shown to inhibit angiogenesis
by upregulating nitric oxide and reducing growth and chemotactic factor production for
monocytes and endothelial cells (Hallene et al., 2006; K. J. Kim et al., 1993; Takano,
Ishikawa, Matsuda, Yamamoto, & Matsumura, 2014; Yang et al., 2003; Zeiher,
Fisslthaler, Schray-Utz, & Busse, 1995; H. Zheng et al., 2011).
Vascular endothelial growth factor (VEGF) plays a pivotal role in angiogenesis by
acting as a chemotactic factor for endothelial cells and monocytes (Heil et al., 2000;
Hong, Ryu, & Han, 2005). It also promotes an increase in permeability of blood vessels
and cell adhesion at the site of angiogenesis (Heil et al., 2000; Hong et al., 2005; P. Lee
et al., 2002; Zeiher et al., 1995). Angiogenesis is particularly important during placental
and fetal development because proper blood flow is necessary for both the health of the
pregnancy and for the fetus’ development (Mayhew, Charnock-Jones, & Kaufmann,
2004; Reynolds et al., 2006). This blood flow aids in nutrient transfer from mother to
fetus (Mayhew et al., 2004; Reynolds et al., 2006). There is evidence that when uteroplacental blood flow and placental blood flow is restricted there is decreased fetal
growth, vascularity, and an increased probability for compromised pregnancies

19
(Crivellato, 2011; Mayhew et al., 2004; Reynolds et al., 2006). The role of angiogenic
factors on organogenesis demonstrate these factors are able to signal to organs to
instruct patterning and morphogenesis during formation (Crivellato, 2011). For example,
VEGF signaling plays a necessary role in heart development, neural stem cell
proliferation, kidney vasculogenesis, glomerulogenesis, and tubulogenesis,
physiological and pathological lung formation, bone, and neural development
(Crivellato, 2011).
Together, these data demonstrate that angiogenesis is necessary for proper
development in the placenta and fetus. IFN-β is a potent inhibitor of angiogenesis,
suggesting that this cytokine can impede both brain and fetal development during viral
infection. Inflammation resulting from responding to infection can be detrimental to the
fetus/neonate developmentally, where tolerance allows for proper growth.
Angiogenesis, Monocytes, and Neuropilin-1
The previous section highlights the importance of angiogenesis during fetal
development and how angiogenesis can be disrupted when the immune system
becomes inflammatory. Originally, endothelial cells were highlighted as the cell type
involved in angiogenesis. However, it is now known that monocytes and macrophages
also play key roles in angiogenesis (Dalton et al., 2014; Fantin et al., 2013; Gerhardt et
al., 2004; P. Lee et al., 2002). Hypoxic conditions stimulate angiogenesis. This is due to
the fact that myeloid cells respond to hypoxia by producing hypoxia inducible factors 1alpha and 2-alpha (HIF-1α and HIF-2α, respectively). These factors promote
transcription of genes involved in angiogenesis, such as VEGF (Büchler et al., 2003;
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Dalton et al., 2014; Krock, Skuli, & Simon, 2011; Murdoch, Muthana, Coffelt, & Lewis,
2008; Ramakrishnan, Anand, & Roy, 2014).
VEGF is the key cytokine involved in the recruitment of monocytes and is a
necessary factor for angiogenesis (Carmeliet et al., 1996; Heil et al., 2000; Hong et al.,
2005). Endothelial cells, macrophages, and monocyte-derived dendritic cells (mo-DCs)
can all produce VEGF after HIF exposure (Dalton et al., 2014; Plaks et al., 2008).
Depletion of monocytes and mo-DCs has been found to terminate pregnancies due to
loss of production of VEGF and subsequent reduced angiogenesis (Plaks et al., 2008).
Monocytes can express all four VEGF receptors, VEGFR1, VEGFR2, VEGFR3, and
neuropilin-1 (NRP-1) (Alkharsah, 2018; Gelfand et al., 2014). VEGF acts as a
chemoattractant for monocytes in two ways: (1) by directly binding VEGF receptors and
(2) through stimulating endothelial cells to produce monocyte chemoattractant protein
(MCP-1); both of which attract monocytes toward the endothelial tip during
angiogenesis (Dejda et al., 2014; Heil et al., 2000; Hong et al., 2005). Once recruited to
the tip, these monocytes produce platelet-derived growth factor (PDGF) which promotes
mitotic activity in endothelial cells and vascular smooth muscle cells (Carrer et al.,
2012). These monocytes also endocytose oxidized lipids, turning them into foam-cells.
These foam cells stimulate smooth muscle cell migration and stimulate a change in
endothelial function leading to vascular remodeling (Dalton et al., 2014; Jaipersad, Lip,
Silverman, & Shantsila, 2014).
NRP-1 is a pleotropic receptor that is able to bind VEGF, SEMA3A, and TGF-β
(Roy et al., 2017). The expression of NRP-1, the fourth VEGF receptor, on monocytes
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has been found to be essential for angiogenesis (Dejda et al., 2014; Fantin et al., 2013;
Gerhardt et al., 2004; P. Lee et al., 2002). NRP-1 knockout mice die by embryonic day
13 due to a lack of vascular development. This receptor allows for the monocytes to
migrate toward VEGF where the monocytes can then aid in promoting angiogenesis
(Dejda et al., 2014; Fantin et al., 2013; Gerhardt et al., 2004; P. Lee et al., 2002). The
importance of angiogenesis and monocyte recruitment is well understood in the context
of development. However, it is not well known what regulates the expression of NRP-1
on monocytes.
Immune Modulation by Calcitriol
Calcitriol Biosynthesis
Vitamin D is an essential vitamin for humans. Originally discovered due to an
increase in rickets during the Industrial Revolution, vitamin D was first described to be
helpful aiding in calcium uptake (McCollum, Simmonds, Becker, & Shipley, 1922;
Mellanby, 1989). Vitamin D is a fat-soluble vitamin which is found naturally in fatty fish,
beef liver, cheese, egg yolks, and fortified foods such as dairy products, orange juice,
and cereal. However, the main source of vitamin D occurs from synthesis in the skin
after exposure to UV radiation, such as the sun (Holick et al., 1980; Holick,
MacLaughlin, & Doppelt, 1981; Holick et al., 1979).
UV-B irradiation of the skin leads 7-dehydro-cholesterol (7-DHC, also known as
pro-vitamin D3) to convert into pre-vitamin D3, where heat then gradually converts it into
vitamin D3 (Feingold et al., 2000; Holick et al., 1980; Holick et al., 1981; Holick et al.,
1979; Windaus, Schenck, & von Werder, 1936). Vitamin D3 synthesized in the skin is
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the same as what is derived from animal food sources, and we can also gain vitamin D 2
from plant sources (Askew, Bourdillon, Bruce, Jenkins, & Webster, 1930; Feingold et
al., 2000). From here, vitamin D3/2 is transported to the liver. In the liver, enzymes
CYP2R1 and CYP27A1 hydroxylate vitamin D3/2 into 25(OH)D (calcidiol), which is the
major circulating form of vitamin D (Ichikawa et al., 1995; Thacher, Fischer, Singh,
Roizen, & Levine, 2015; Usui, Noshiro, & Okuda, 1990; J. G. Zhu, Ochalek, Kaufmann,
Jones, & Deluca, 2013). Here, calcidiol circulates to the kidneys or encounters
macrophages which express CYP27B1. CYP27B1 further hydroxylates calcidiol into
1α,25(OH)2D (calcitriol), which is the active metabolite of vitamin D that mediates the
hormonal and immunological actions of vitamin D (Feingold et al., 2000; G. K. Fu et al.,
1997; Shinki et al., 1997; St-Arnaud, Messerlian, Moir, Omdahl, & Glorieux, 1997;
Takeyama et al., 1997). Calcitriol is then released into the blood for circulation (Bikle,
Gee, Halloran, & Haddad, 1984; Bikle, Siiteri, Ryzen, & Haddad, 1985; Feingold et al.,
2000). Typically, this transport is mediated by the vitamin D binding protein (VDBP) or
albumin (Bikle et al., 1984; Bikle et al., 1985; Feingold et al., 2000). Once released from
VDBP, calcitriol is able to enter cells where it can bind the vitamin D receptor (VDR) to
further mediate transcription (Feingold et al., 2000).
Calcitriol Mode of Action
Calcitriol is the ligand for the vitamin D receptor (VDR). The VDR is located in the
cytoplasm of most immune cells and is a nuclear hormone receptor (Bikle, Gee, & Pillai,
1993; Carlberg & Polly, 1998). Upon binding calcitriol, the VDR heterodimerizes with the
retinoid X receptor (RXR) and the complex translocates to the nucleus (Bikle et al.,
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1993; Carlberg & Polly, 1998; Liao, Ozono, Sone, McDonnell, & Pike, 1990; Schräder,
Bendik, Becker-André, & Carlberg, 1993). Two exceptions to this rule are the VDR
binding to the retinoic acid receptor (RAR) or the thyroid receptor (TR), rather than RXR
(Schräder et al., 1993; Schräder, Müller, Nayeri, Kahlen, & Carlberg, 1994). Once in the
nucleus, the VDR binds to DNA sequences on gene promoter regions known as vitamin
D response elements (VDREs). The VDR also has an AF-2 domain, an area that can
bind coactivators (Aranda & Pascual, 2001; Castillo, Jimenez-Lara, Tolon, & Aranda,
1999; S. Kim, Shevde, & Pike, 2005; Leo & Chen, 2000; Oda et al., 2003). Here,
coactivators are able to bridge the gap between the VDR complex and the RNA
polymerase transcription initiation complex (Aranda & Pascual, 2001; Castillo et al.,
1999; S. Kim et al., 2005; Leo & Chen, 2000; Oda et al., 2003).
VDREs are a specific DNA-binding domain for the VDR that follow a hexameric
DNA sequence. The hexameric consensus sequence is: RGKTSA (R=A or G, K=G or T,
S=C or G) (Carlberg & Polly, 1998; Ramagopalan et al., 2010). The complex of VDR,
RXR, a VDRE, and any coactivators are considered a molecular switch for calcitriol
responsive genes (Aranda & Pascual, 2001). However, there are exceptions to this rule
involving direct repeats (DR) of two consensus sequences with 3-4 intervening
nucleotides (DR3-type and DR4-type, respectively) (Carlberg et al., 1993; Quack &
Carlberg, 2000; Schräder, Nayeri, Kahlen, Müller, & Carlberg, 1995). The final
exception occurs when there are everted repeats (ER-type) response elements with 6-9
spacing nucleotides (ER6-9, respectively) (Schräder et al., 1994; Schräder et al., 1995).
With all of these exceptions, there are hundreds of potential combinations of VDREs on
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a DNA promoter region allowing for calcitriol to impact the transcription of hundreds of
genes.
The Effect of Calcitriol on the Immune System
Calcitriol is a key immunomodulatory molecule that affects the proliferation and
differentiation of multiple immune cells. Our recent study demonstrated that calcitriol
suppresses the expression of AhR by activated T cells and inhibits Th9 differentiation
(Takami, Fujimaki, Nishimura, & Iwashima, 2015). AhR was previously found to play a
role in modulating the Th1/Th2 balance towards a Th1 dominant response and is also
necessary for Th22 induction (Negishi et al., 2005). Our previous data along with others
have shown that calcitriol treatment of CD4 T cells, naïve, memory, in vivo, or in the
context of PBMCs, leads to a reduction in Th1 associated cytokines such as IL-2, TNFα, and IFN-γ (Alroy, Towers, & Freedman, 1995; Cantorna, Yu, & Bruce, 2008; Jeffery
et al., 2009; Mahon, Wittke, Weaver, & Cantorna, 2003; Mattner et al., 2000; Panichi et
al., 1998; Rausch-Fan et al., 2002; Reichel, Koeffler, Tobler, & Norman, 1987; Saggese,
Federico, Balestri, & Toniolo, 1989; Staeva-Vieira & Freedman, 2002). Murine models
have found evidence of an increase in Th2 cytokines upon vitamin D exposure and it
has been reported that calcitriol treatment also leads to an increase in Tregs (Daniel,
Sartory, Zahn, Radeke, & Stein, 2008; Gorman et al., 2007; Jeffery et al., 2009;
Nashold, Hoag, Goverman, & Hayes, 2001; Penna et al., 2005; Prietl et al., 2010;
Sloka, Silva, Wang, & Yong, 2011). Calcitriol has also been found to inhibit Th17
differentiation and downregulate Th17 cytokine production (S. H. Chang, Chung, &
Dong, 2010; Daniel et al., 2008; Moniaga, Egawa, Miyachi, & Kabashima, 2013; Tang et
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al., 2009; H. Zhang, Shih, & Zhang, 2013). The skew away from Th1, Th9, Th17, Th22
along with promoting Th2 and Treg differentiation supports claims that calcitriol
promotes an anti-inflammatory immune response and helps aid to combat
autoimmunity.
In addition to T cells, calcitriol also plays a role on monocytes and their
differentiation into macrophages. Calcitriol has been found to reduce myeloid proinflammatory cytokine production, while reducing inflammatory responses to IFN-γ and
lipopolysaccharide (LPS) stimulation (L. Chen, Eapen, & Zosky, 2017; Helming et al.,
2005; Y. Zhang et al., 2012; X. Zhu et al., 2019). This nutrient has also been found to
inhibit macrophage polarization to M1 macrophages, while promoting polarization to M2
macrophages (S. Liang, Cai, Li, & Yang, 2019; Wasnik et al., 2018; X. Zhu et al., 2019).
M1 macrophages are pro-inflammatory, while M2 macrophages are known to have
suppressive functions and assist in wound healing (Funes, Rios, Escobar-Vera, &
Kalergis, 2018). Calcitriol also inhibits the production of IL-12 by myeloid cells, which
helps explain the reported reduction in Th1 cells (D'Ambrosio et al., 1998). Similar to the
effect on T cells, these results further demonstrate that calcitriol skews towards an antiinflammatory immune response.
Calcitriol’s Effect on Tissue Development and Regeneration
While calcitriol has multiple effects on immune cells, it also plays a role in
embryogenesis and vascular regeneration. In zebrafish models, it has been found that
the growth rate and length of the embryos were increased when treated with vitamin D
analogs (Han et al., 2019). Cell proliferation and growth was also enhanced throughout
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embryonic tissues, specifically in the liver and cardiomyocytes (Han et al., 2019).
Angiotensins are another factor essential for healthy angiogenesis. One study found
that calcitriol treatment could reduce the severity of symptoms from rats being treated
with angiotensin II antagonists during lactation (de Almeida, Francescato, da Silva,
Costa, & Coimbra, 2017). These calcitriol-supplemented rats had improved renal
function and structure in comparison to those without calcitriol and showed marked
reduction in inflammation (de Almeida et al., 2017). Endothelial cells after exposure to
calcitriol also demonstrated enhanced proliferation and increased tubule formation,
along with increased growth factor production, including VEGF (Grundmann et al.,
2012).
Calcitriol has also been reported to promote vascular regeneration in a human
supplement trial (Wong et al., 2014). The prevalence of angiogenic myeloid cells
increased in these patients (Wong et al., 2014). In mice from the same study,
supplementation of calcitriol promoted re-endothelialization in an injury and artery
ligation model in a VDR dependent manner (Wong et al., 2014). In two studies, calcitriol
was able to increase HIF-1α, which is known to lead to VEGF production in hypoxic
conditions leading to increased angiogenesis (Büchler et al., 2003; Caponegro, Moffitt,
& Tsirka, 2018; Dalton et al., 2014; Heil et al., 2000; Jiang, Zheng, & Teegarden, 2010;
Krock et al., 2011; Murdoch et al., 2008; Ramakrishnan et al., 2014; Wong et al., 2014).
In support of this, two other studies found that calcitriol promotes VEGF production
(García-Quiroz et al., 2014; Grundmann et al., 2012). However, the opposite has been
observed using cancer cell lines, where one study reported that calcitriol inhibits HIF-1α
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production and yields reduced angiogenesis (Ben-Shoshan et al., 2007). This
discrepancy may be due to the fact that transformed cancer cell lines were used for the
later study, where the other two studies were using untransformed cells. More studies
will need to investigate this further.
Lastly, calcitriol plays a positive role during gestation. IL-6, TNF-α, and IFN-γ
have negative effects on fetal development (Yockey & Iwasaki, 2018). Calcitriol reduces
production of all three of these cytokines during gestation (Olmos-Ortiz, Avila, DurandCarbajal, & Díaz, 2015). Taken together, calcitriol promotes embryogenesis,
vascularization, angiogenesis, and suppresses inflammatory cytokine production during
development.
Calcitriol’s Effect on Combating Autoimmunity
Experimental autoimmune encephalomyelitis (EAE) is the murine model for
multiple sclerosis (MS). These diseases are characterized by paralysis, auto-antibodies
against myelin basic protein, and lesions in the brain. The most common way to induce
EAE is through treatment with myelin oligodendrocyte glycoprotein (MOG); disease
symptoms begin roughly 9-14 days post-treatment (Bittner, Afzali, Wiendl, & Meuth,
2014; Miller & Karpus, 2007). EAE is scored on a scale of 0-5, signifying: (0) no change,
(1) limp tail, (2) limp tail and weakness of the hind legs, (3) limp tail with paralysis of at
least two legs, (4) limp tail with complete hind leg and partial front leg paralysis, and (5)
severe paralysis or death to paralysis (Miller & Karpus, 2007). In 1991, it was
discovered that calcitriol treatment prior to immunization prevented the development of
EAE and the inhibited development of auto-antibodies against myelin basic protein
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(Lemire & Archer, 1991). From this point on, the field has been studying to better
understand how calcitriol/vitamin D have a protective effect against the development of
autoimmunity. Studies have found that indeed, the VDR is necessary for the protective
effects against autoimmune disorders (Mayne, Spanier, Relland, Williams, & Hayes,
2011; Meehan & DeLuca, 2002b). While the dominant amount of this work has been
done with EAE/MS, calcitriol has also been found to be preventative against other
autoimmune disorders such as systemic lupus erythematosus (SLE) and rheumatoid
arthritis (Iruretagoyena, Hirigoyen, Naves, & Burgos, 2015; H. L. Zhang & Wu, 2010).
Patient data has also touted remarkable success in supplemental calcitriol alleviating
symptoms (Shaygannejad, Janghorbani, Ashtari, & Dehghan, 2012; Wingerchuk,
Lesaux, Rice, Kremenchutzky, & Ebers, 2005).
Th1 and Th17 cells have been reported as two key Th subsets that are
responsible for autoimmune disease when they gain the ability to react to self-proteins.
Similar to in vitro and mouse data, calcitriol was found to reduce Th1 development in
the context of EAE due to decreased IL-12 production by monocytic cells, leading to
diminished production of IFN-γ and IL-2 in the system (Mattner et al., 2000). IL-17A
production from Th17 cells has also been known to exacerbate EAE, and in IL-17A
knockout mice, EAE clinical score is significantly reduced (Komiyama et al., 2006).
Calcitriol in the context of EAE reduced Th17 differentiation and IL-17A production at
the transcriptional level in a VDR-dependent manner (J. H. Chang, Cha, Lee, Seo, &
Kweon, 2010; Joshi et al., 2011). The effect of calcitriol on CD8 T cells has been found
to be insignificant in the context of autoimmunity (Meehan & DeLuca, 2002a).
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While calcitriol treatment causes a reduction in inflammation by suppressing Th1
and Th17 cells, it has also been found in a VDR-specific manner to induce
Helios+Foxp3+ T cells in the central nervous system (CNS) (Nashold, Nelson, Brown, &
Hayes, 2013; Spanier, Nashold, Mayne, Nelson, & Hayes, 2015). These Tregs then
suppress inflammatory responses in the central nervous system to combat disease
(Nashold et al., 2013; Spanier et al., 2015). In another study, calcitriol was unable to
inhibit EAE in mice with disrupted IL-10 signaling, suggesting the importance of IL-10
production by Tregs (Spach, Nashold, Dittel, & Hayes, 2006). Lastly, calcitriol
supplementation also increases CTLA-4 expression on T cells which can lead to
increased suppression of T cell responses (Spanier, Nashold, Nelson, Praska, & Hayes,
2020).
Myeloid cells are also affected by calcitriol in EAE. Calcitriol has been reported to
reduce toll-like-receptor (TLR) expression in monocytes, most significantly TLR8 and its
adaptor protein, MyD88 (B. Li et al., 2013). This reduction lead to reduced inflammatory
cytokine production (TNF-a and IL-1β) by monocytes (B. Li et al., 2013). Another study
found that chemokine production and monocyte recruitment were inhibited after calcitriol
treatment, thus reducing infiltration of inflammatory monocytes and macrophages into
the CNS (de Oliveira et al., 2020; Nashold, Miller, & Hayes, 2000; Pedersen, Nashold,
Spach, & Hayes, 2007). Overall, these results demonstrate that calcitriol promotes an
anti-inflammatory immune response in the context of autoimmunity by reducing
inflammation from Th1, Th17, monocytes, and macrophages while promoting Treg
induction, CTLA-4 expression, and IL-10 production.
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Purpose of Dissertation
To study neonatal immune tolerance, our lab collects umbilical cord blood (UCB)
at birth and we investigate the response of T cells against antigen receptor stimulation.
Here, I define a new type of Foxp3+ Treg, named bidirectional T cells (BiT) derived from
UCB. BiTs are induced by monocytes that present transforming growth factor-beta
(TGF-β), a necessary molecule for Treg induction. BiTs express classical Treg markers
but also express other T cell markers and pro-inflammatory cytokines. This profile
suggests that BiTs are capable of both suppressing and activating the immune system.
Based on these differences, we hypothesized that BiTs are genetically distinct from in
vitro induced Tregs (iTregs) and thymus derived Tregs (tTregs). To test this, we
performed RNA-Seq on these different Treg populations and compared differentially
expressed genes.
In an effort to determine if any factors could promote or hinder BiT inductions, I
investigated the effects of calcitriol and IFN-β. These nutrients were chosen because
vitamin D is known to promote an immunosuppressive environment and aids in healthy
fetal development, while IFN-β has an opposite effect. I have demonstrated that
physiological levels of calcitriol increase BiT induction and expression of NRP-1 by
monocytes. Conversely, IFN-β treatment significantly reduces BiT induction and NRP-1
expression. NRP-1 is a surface receptor capable of binding multiple ligands, one of
which is TGF-β which is a necessary molecule for Treg induction. Thus, we
hypothesized that calcitriol promotes BiT development due to an increase in TGF-β
signaling and availability from the NRP-1 upregulation on monocytes.
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Our lab previously reported that calcitriol inhibits Th1 and Th9 differentiation.
However, the function and phenotype of T cells that develop under these conditions
were not assessed. The literature suggests that calcitriol promotes a suppressive
environment, however the mechanism for suppression by these T cells is unknown. To
assess the direct effect of calcitriol on T cells, we determined the phenotypic and
functional changes of T cells stimulated in calcitriol sufficient conditions. Our previous
work demonstrated that calcitriol reduces T cell expression of the aryl hydrocarbon
receptor (AhR), a transcription factor that functions as a co-factor for TGF-β signaling.
Thus, I hypothesized that calcitriol also has a direct effect on T cells that aid in BiT
induction. My dissertation research aimed to investigate how BiTs differ from previously
defined Tregs and understand the effect of calcitriol on monocytes and T cells to
enhance BiT induction.

CHAPTER TWO: MATERIALS AND METHODS
Cell Preparation and Reagents
BiT Cultures
Total umbilical cord blood mononuclear cells from 3 donors were stimulated with
recombinant animal-free human IL-2 (10 ng/ml; Peprotech, Rocky Hill, NJ) and soluble
anti-CD3 (0.2 μg/ml) in RMPI 1640 (GE Healthcare Hyclone, Chicago, IL) supplemented
with 10% fetal calf serum (Gemini Bio-Products, West Sacramento, CA). Cells were split
1:1 every 2-3 days with fresh IL-2 media. CD4+CD8-CD25+Foxp3+ status was
analyzed after 13 days of culture. CD4+ samples with greater than 80% CD25+FOXP3+
status were harvested on day 14 and sorted for CD4+CD25+ cells using a FACS Aria
(BD Biosciences, San Jose, CA).
iTreg and Effector T Cell Cultures
1.3x105 naïve CD4 T cells from UCB were plated in a 96 well U-button plate in
200µl of media supplemented with 10 ng/ml of recombinant human IL-2 and TGF-β
(Peprotech) and immunocult activators following manufacturer’s instructions (Stem Cell
Technologies). For effector T cells, the same culture was used but without TGF-β. Cells
were split as necessary and harvested on day 7. Purity was assessed by labeling for
CD4, CD25, and Foxp3. Donors with greater than 80% purity were subject to cell sorting
(BD FACS Aria) for CD4+CD25+ cells for iTreg and CD4+CD25- for effectors.
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tTreg Cultures
Adult PBMCs were harvested and subject to the human Treg isolation kit (Stem
Cell Technologies). These cells were cultured with recombinant human IL-2 (10 ng/ml;
Peprotech) in RMPI 1640 (GE Healthcare Hyclone, Chicago, IL) supplemented with
10% fetal calf serum (Gemini Bio-Products, West Sacramento, CA) and Immunocult
activators following manufacturer’s instructions (Stem Cell Technologies). Cells were
split 1:1 every 2-3 days with fresh IL-2 media. CD4+CD25+CD127loFoxp3+ status was
analyzed after 13 days of culture. CD4+ samples with greater than 80% CD25+FOXP3+
status were harvested on day 14 and sorted for CD4+CD25+ cells using a FACS Aria
(BD Biosciences, San Jose, CA).
Calcitriol-Treated T Cell Cultures
Naïve CD4 T cells were harvested from adult human PBMCs. Blood collection
was performed with IRB approval (Loyola University Chicago (IRB# 203678081012)).
Adult human PBMCs were collected from de-identified donors that met our collection
criteria (exclusion criteria: evidence of active malignancies, use of medications that
affect the immune system (such as glucocorticoids and immunosuppressants),
uncontrolled hyper- or hypothyroidism, presence of an autoimmune disease, and/or
presence of an active infection). Naïve CD4 T cells were obtained via negative selection
using an EasySep™ Human Naïve CD4 T Cell Enrichment Kit (Stem Cell Technologies,
Vancouver, BC, Canada) or a MojoSort™ Human CD4 Naïve T cell Isolation Kit
(BioLegend, San Diego, CA). All samples maintained at or above a 90% purity rating
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(not shown). Cells were treated once at the time of stimulation with calcitriol (10 nM;
Sigma-Aldrich, St. Louis, MO) and 10 ng/ml IL-2 (Peprotech, Rocky Hill, NJ) and plated
on non-treated CytoOne 48 well plates (USA Scientific, Ocala, FL) that were coated with
anti-CD3 (OKT3; 5ug/ml; BioLegend) and anti-CD28 (28.2; 5ug/ml; BioLegend) for cell
stimulation. Control cells were treated with dimethyl sulfoxate (DMSO) since calcitriol
was reconstituted in DMSO.
Monocyte Cultures
CD14+ monocytes were enriched from mononuclear cells using an EasySep
enrichment kit (Stem Cell Technologies). All samples maintained at or above a 90%
purity rating (not shown). CD14+ monocytes were cultured in the presence or absence
of 10 ng/ml IFN-β (Peprotech) and RPMI media supplemented with 10% fetal calf serum
(GE Life Sciences and Gemini Bio).
Transwell Migration Assay
Cells were pretreated overnight with or without 10 ng/ml IFN-β. The following
day, cells were washed and resuspended in 5x105/200ul. 200μl of cells were added to
an 8-micron pore 24-well transwell plate (Corning). At the bottom of the well, 800μl of
regular culture media or 50 ng/ml recombinant VEGF-165A supplemented media was
plated (BioLegend). The assay sat overnight in a CO2 incubator at 37°C. The next day,
transwells were removed and cells at the bottom were collected and counted. Fold
change is the calculation of the number of cells that migrated towards VEGF divided by
the number of cells that migrated in the absence of VEGF.
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Phenotype Analysis of BiT and Calcitriol Treated T cells
Suppression Assay
4 days prior to the suppression assay, naïve CD4 T cells were isolated, treated,
and stimulated as described above. On day 4 post-treatment, cells were checked for
expression of PD-L1, CTLA-4, CD4, and Foxp3. An allogeneic donor was collected,
naïve CD4 T cells were stained with CFSE (BioLegend) and used as responder cells.
Remaining PBMCs were sorted for size gated cells that were CD3 negative on a BD
FACS Aria to collect APCs (BD BioSciences). APCs were irradiated at 3000 rad. tTregs,
calcitriol-treated and DMSO-treated T cells were stained with cell trace violet (CTV;
BioLegend). Responder cells were stimulated with anti-CD3 (0.2 μg/ml) and cultured
with APCs at a 1:1 ratio (50,000 cells each) in the presence or absence of the
respective CTV labeled suppressor populations in a dose-dependent manner. The
percent proliferation of responders and suppressors was determined after 6 days of
coculture via percent diluted CFSE and CTV, respectively, using flow cytometry.
Cytokine Expression
Cell supernatants were harvested 5 days post-treatment. Supernatants were
analyzed for expression of T cell cytokines using the LEGENDplex Human Th cytokine
panel (BioLegend) according to manufacturer’s instructions on a BD FACS CANTO II
Flow cytometer (BD Biosciences).
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Generation of a NRP1 Knockout THP-1 cell line using CRISPR/Cas9 Genome
Editing
Generation of a NRP1 knockout THP-1 cell line was achieved by the transduction
of LentiCRISPRv2 (Addgene 52961), encoding CRISPR guide RNA (gRNA) against
human NRP-1. Guide sequences were generated using the CRISPR design tool
(www.crispr.mit.edu). The sequence for the CRISPR gRNA targeting NRP-1 was: 5’GTTGCGAAAAGCGCCGGCCG-3’. This oligonucleotide was annealed and cloned into
a modified LentiCRISPRv2 (puromycin resistance was replaced by mCherry
expression). Lentivirus was prepared by transfecting equal amounts of vesicular
stomatitis virus G, psPAX2 (11348; Didier Trono, NIH AIDS Reagent Program), and
LentiCRISPRv2 (containing the guide RNA of interest) into HEK293T cells. The viral
supernatant was harvested 48 hours post-transfection, filtered through 0.45-μm filters
(Millipore), and applied to THP-1 cells. 48 hours post-transduction, cells were sorted for
mCherry expression via a BD FACS Aria cell sorter with 1 cell per 96 well, and singlecell clones were generated (BD Biosciences).
TGF-β Bioassay
MFB-F11 cells (TGFβ-1 deficient MEFs transfected with a SMAD-binding element
promoter fused to secrete an embryonic alkaline phosphatase) were described
previously and used as reported (Tesseur, Zou, Berber, Zhang, & Wyss-Coray, 2006).
Briefly, culture supernatants of transduced THP-1 lines were collected after 24 hours
and added to MFB-F11 cells. After 48 hours, these cumulative supernatants were
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treated with PNPP in alkaline conditions. If active TGF-β was present in the culture,
then color change was assessed via a plate reader at 450nm. As a control, THP-1
supernatants were first acid-treated prior to addition to MFB-F11 cells to cleave latentTGF-β and demonstrate total TGF-β in the culture.
Western Blot Analysis
Equal numbers of cells (1.0x106 cells/100µl) were lysed in SDS sample buffer (2%
SDS, 125mM DTT, 10% glycerol, 62.5mM Tris-HCl (pH 6.8)) and proteins were subjected
to Western blot analysis using the following antibodies: Histone-H3 (BioLegend); SOS1
(Cell Signaling Technologies); SGK1 (Santa Cruz Biotechnologies); and THEMIS (Santa
Cruz Biotechnologies). Signals were detected with the ECL system (GE Healthcare,
Piscataway, NJ). The relative intensity of each band was determined by ImageJ software
(National Institutes of Health) after normalization using Histone-H3 as the control.
Flow Cytometry
For BiT studies: cells were harvested after 14 days (7 days for iTregs) and surface
labeled with anti-CD3, anti-CD8, anti-CD4, anti-CD25, anti-CD96, and anti-CD33, and
intracellularly labeled with anti-Foxp3 (BioLegend). Cells were analyzed on a BD FACS
CANTO II Flow cytometer (BD Biosciences). t-SNE analysis was performed using
FlowJo’s built in t-SNE and concatenation packages. Data analysis was performed using
FlowJo (FlowJo, LLC, Ashland, OR). For calcitriol studies: cells 3 to 5 days post-treatment
were harvested and surface labeled with anti-PD-L1, anti-CTLA4, anti-CD4, anti-CD25,
and anti-PD-1, and intracellularly labeled with anti-Foxp3 and anti-CTLA4 (BioLegend and

38
BD Biosciences, San Jose, CA). Cells were analyzed on a BD FACS CANTO II Flow
cytometer (BD Biosciences). Data analysis was performed using FlowJo (FlowJo, LLC,
Ashland, OR). Surface CTLA-4 labeling was performed on ice, when labeling for surface
and intracellular CTLA-4, a different clone with a different fluorophore conjugated to it was
utilized after fixing and permeabilizing (True Nuclear Kit, BioLegend) the cells for
intracellular CTLA-4.
CTLA-4 Promoter Analysis for VDRE
The CTLA-4 promoter was assessed using the Eukaryotic Promoter Database
(EPD) and the PROMO database for potential VDR binding sites (Cavin Périer, Junier,
& Bucher, 1998; Farré et al., 2003; Messeguer et al., 2002).
Genotype Analysis of BiT
RNA Isolation
Naïve CD4 T cells were collected as described above. Unstimulated cells were
isolated for RNA on day 0 to establish a baseline level of naïve cell expression. For
calcitriol studies, cells were treated and expanded for 4 days as described above. RNA
was isolated using a RNeasy isolation kit (Qiagen, Germantown, MD). For RNAseq
analysis, cells were isolated on day 7 (iTregs) or on day 14 (BiT, tTregs, effector T
cells).
RNASeq Analysis of T Cell Subsets
Quality of samples were checked using FastQC (version 0.72). To improve
sequence quality, samples were cleaned by Trimmomatic (version 0.36.5) to remove
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any low-quality bases and the Illuminaclip function was used to clip Illumina adaptor
sequences. The following parameters were used: LEADING: 28; TRAILING: 28;
MINLEN: 30. The dataset was then aligned to the human Hg19 reference genome using
RNA STAR (version 2.6.0b-1). Gene counts were then obtained using featureCounts
(version 1.6.3). Data was normalized and differentially expressed genes were
determined using DESeq2 (version 2.11.40.2), afterwards the dataset was filtered
(using Filter version 1.1.0) to show genes with significant difference (p<0.05) and to
extract genes with greater than log 2-fold difference.
qPCR
RNA was isolated with RNeasy kit from cells at stated times pre- and poststimulation. Isolated RNA was reverse-transcribed with RT2 First Strand Kit. The qPCR
reactions were performed using RT2 Kit (Qiagen). The qPCR reaction is 1) 95 °C for 10
min, 2) 95 °C for 15 s, 3) 60 °C for 1 min, and a repeat of steps 2 and 3 for 40 cycles.
Bisulfite Sequencing
Only male donors were used as all female cells carry a methylated allele from
one of the X chromosomes. Cells were isolated and cultured as described above, only
donors with >80% purity were used. DNA isolation was conducted using DNeasy Blood
and Tissue Kit (Qiagen) and bisulfite conversion was conducted following the
manufacturer’s protocol (Single-step EZ DNA methylation-Direct Kit, Zymo Research).
Statistical Analysis
Statistical analysis was performed using GraphPad Prism software (GraphPad
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software, CA). One-way ANOVA with Tukey’s posttest for multiple comparisons were
used to compare changes in expression between multiple groups. When comparing only
two groups, student’s t-tests were performed.

CHAPTER THREE: RESULTS
SECTION 1: Characterization of Bidirectional T regulatory cells (BiTs) from
Umbilical Cord Blood versus iTregs and tTregs
BiTs are Suppressive but Express Inflammatory Cytokines
Previous work from our lab (generated by Alex Nelson, M.S.) uncovered striking
differences between BiT and tTregs from adult peripheral blood (APB) (J. Lee et al.,
2020). On initial harvest, UCB shows 1.2% Tregs, where adult blood has 2.2% Tregs
defined by Foxp3+CD4+ cells (Figure 1A). After BiT induction cultures in vitro, we saw
that 74.1% of UCB CD4 T cells differentiate into Tregs (BiT) while only 18.4% of adult
blood CD4 T cells differentiated into Tregs (Figure 1B/C). These BiT cells are also
functionally suppressive, as tested by a standard suppression assay (Figure 1D). Our
lab has found that these Tregs are not an expansion from previously existing
CD4+CD25+ cells, but rather induction of new cells. This has been tested by depletion
of CD4+CD25+ cells (pre-existing Tregs, purity >90%) and then performing a BiT
induction culture (Figure 1E). These data demonstrated that between total UCB and
UCB depleted of CD4+CD25+ cells both induced ~56% BiT. Foxp3 expression is also
stable in BiT, as demonstrated by in vitro expansion for two months, where Tregs from
APB lose their Foxp3 expression after three weeks (Figure 1F).
The lab next questioned whether BiT were different from tTregs in APB and
assessed this by cytokine expression after restimulation on day 14. Nelson found that
41
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BiT expressed GM-CSF in 60% of cells, and IL-8 was expressed in about 30% of cells,
while APB Tregs did not express these cytokines (Figure 2).

Figure 1. Induction of BiT Cells from UCB Compared to APB Tregs.
(A) CD4 and FOXP3 expression among freshly isolated UCB and APB. (B-C) Foxp3
and CD25 expression in CD4 and CD8 T cells after anti-CD3 and IL-2 stimulation for 14
days; n=7. (D) Suppression assay depicting the proliferation of responder T cells
(CFSE) in the presence of BiT (solid line) or non-Treg cells (dashed line). (E) Foxp3 and
CD25 expression from total UCB and CD4+CD25+ depleted UCB cultures expanded for
14 days in IL-2 and anti-CD3. (F) Foxp3 and CD127 expression after prolonged in vitro
expansion of BiT and tTregs from APB. Figure adapted from (J. Lee et al., 2020), work
done by Jessica Lee, MD, Ph.D.
These data suggest that BiT induced from UCB are phenotypically different from
tTregs found in APB. We were especially interested in the differences in cytokine
expression and the prolonged stability of Foxp3, as tTregs are known to be key immune
suppressors but the production of GM-CSF and IL-8 by BiT may indicate the ability to
promote an inflammatory response, particularly in innate immune cells. Interestingly,
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BiTs did not produce IL-10, a cytokine produced by iTregs (data not shown). Based on
these data, we hypothesized that BiTs are genetically distinct from tTregs and iTregs
and sought to determine their genetic profile through methylation studies and RNAsequencing.

Figure 2. Intracellular Cytokine Production by BiT from UCB and tTregs from
APB.
GM-CSF (left) and IL-8 (right) production by BiT and tTregs after re-stimulation on Day
14 with PMA and ionomycin (+) or no stimulation (-). Data represent the average of 3-7
donor samples, *p<.05, **p<.005, ***p<.0005, and ****p<.0001. Figure adapted from (J.
Lee et al., 2020), work done by Alex Nelson, M.S.
BiTs are Methylated on Foxp3 CNS2
Foxp3+ Tregs can be defined based on of the methylation status of the CNS2
region of the foxp3 promoter, where tTregs are hypomethylated on this region, and
effector T cells, pTregs, and iTregs are hypermethylated on this region. Since BiTs can
be induced from naïve CD4 T cells from UCB, we hypothesized their CNS2 region
would be methylated, similar to iTregs and unlike tTregs. To do this, we isolated DNA
from day 14 BiTs, iTregs, expanded adult tTregs, and effector T cells from UCB male
donors. We chose male donors since males only have one X chromosome, where
Foxp3 is located. This allows for avoiding detection of a silenced X chromosome in
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females. Yi Wei Lim, a member of our lab, then performed bisulfite sequencing, which
converts de-methylated cytosine to uracil, where methylated cytosines remain
unchanged. The Foxp3 CNS2 region has fourteen CpG islands, so we assessed the
level of methylation on these islands. We observed that BiTs had similar methylation to
iTregs and effector T cells, rather than tTregs (Figure 3). Variations in tTreg levels are
most likely due to the presence of pTregs in the culture because the Tregs were
collected from peripheral blood, not the thymus. These data suggest that BiTs are more
akin to induced forms of Tregs, rather than naturally arising tTregs since they do not
have a stabilized CNS2 from de-methylation.

Figure 3. Foxp3 in BiT are Methylated at the CNS2 Site.
Demethylation status at Foxp3 CNS2 CpG sites in BiT, iTreg, tTreg, and UCB effector
cells. Data represent the average of 3-4 donor samples, error bars represent standard
deviation, *p<.05 Figure from (J. Lee et al., 2020), work done by Yi Wei Lim.
RNA-Sequencing and qPCR of Differentially Expressed Genes of BiTs, in
Comparison to tTregs and iTregs
While BiTs seem to be more like effector T cells, pTregs, or iTregs, we know they
have a differing cytokine profile and maintain prolonged Foxp3 expression (Figures 1
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and 2). With the ability to produce GM-CSF and IL-8 but not IL-10, this suggests a
genetically distinct subset of Treg. To determine the genetic profile of BiT, we isolated
RNA from day 14 BiTs (>80% pure CD4+CD25+Foxp3+ population), along with effector
T cells, adult tTregs, and iTregs. We performed RNA-seq and determined differentially
expressed genes (DEGs), defined as p<0.05 and greater than a log 2-fold difference.
From this, we found there are 2016 DEGs between effector T cells, BiT, tTregs, and
iTregs.
Next, we sought to determine whether BiTs expressed genes specific to any
previously defined T helper subsets, which could help us better characterize these cell
types. To achieve this, we analyzed the expression of Th subset specific genes across
effectors, iTregs, tTregs, and BiT (Figure 4). These data indicate that BiT did not fit
uniformly under any of the previously defined T helper subsets, but rather tended to
upregulate 30-40% of genes from each subset (Figure 4).
Since BiT did not fit into a previously defined subset, we sought to determine
potential markers for BiT. From the DEG list, we highlighted four genes of interest.
These genes were highly upregulated by BiTs and have known roles in immune
function. The first gene, THEMIS (thymocyte expressed molecule involved in selection)
is known to play a role in positive T cell selection in late thymocyte development
(Lesourne et al., 2009). This gene is necessary for lineage commitment and maturation
of T cells (Lesourne et al., 2009). THEMIS acts as an adaptor molecule which regulates
TCR signaling and p-ERK by binding Grb2 and LAT (Lesourne et al., 2009). The next
gene, SOS1 (son of sevenless 1), impacts signal transduction in early thymocyte
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development (Kortum et al., 2011). SOS1 is a guanine exchange factor (GEF) for Ras
which in turn activates Ras (Hillig et al., 2019; Innocenti et al., 2002). In effector T cells,
Ras is able to activate RasGRP1, however our lab has found the opposite in tTregs,
where TGF-β suppresses RasGRP1 and there is reduced SOS1 in tTregs in
comparison to effector T cells (Takami, Cunha, Motohashi, Nakayama, & Iwashima,
2018). Since we know that BiTs are likely not tTregs, this gene could be a good marker
since it expresses a gene with typically low expression by Tregs. A third gene that
piqued our interest was SGK1 (serum- and glucocorticoid-regulated kinase 1), which is
known to be critical for development and function of Th17 cells and restrains the
function and development of Treg cells (C. Wu et al., 2018). SGK1 is a Ser/Thr kinase
that regulates stress response and inhibits IL23-R (C. Wu et al., 2018). This gene is
intriguing since Th17 and Tregs are both induced by TGF-β, but Th17 is only induced if
IL-6 is also present. SGK1 is important for this axis; however, we have never detected
the presence of Th17 cytokines in BiTs, suggesting further control of SGK1.
The final gene of interest is CD33 (SIGLEC 3). We were particularly interested in
this gene because the protein resides on the surface of cells which would assist in the
detection of BiTs. However, CD33 is traditionally expressed by myeloid cells, not
lymphocytes. Interestingly, CD33 has ITIM and ITSM, similar to PD-1’s cytoplasmic
domain, and we know that PD-1 signaling has been known to aid in iTreg and pTreg
differentiation. If this marker is found on BiT, it could be uniquely expressed, since it is
typically known to be myeloid restricted. If any of these genes of interest are a marker
for BiT, then we expect to see high expression in BiT but not other Treg populations.
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Figure 4. BiT are not a Previously Defined Th Subset.
Heatmaps of Th subset specific genes comparing Teff, iTreg, tTreg, and BiT; n=3. Blue
signifies downregulation and red signifies gene upregulation. RTE: Recent thymic
emigrant.
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To confirm our RNA-seq results, we performed qPCR on tTreg, iTreg, and BiT
donors for these genes of interest. THEMIS, SOS1, and SGK1 all showed significant
increases in mRNA expression in comparison to tTregs and iTregs, suggesting promise
as BiT specific genes (Figure 5A-C). We were unable to detect CD33 mRNA
expression, which we believe correlates to the small number of counts in the RNA-seq
data (less than 300 reads, data not shown). But these mRNA results demonstrate that
THEMIS, SGK1, or SOS1 could be promising markers for BiTs.

Figure 5. mRNA Expression of BiT Upregulated Genes.
Fold change in mRNA expression for (A) THEMIS, (B) SOS1, and (C) SGK1 in tTreg,
iTreg, and BiT. Data is normalized to respective 18SrRNA as a housekeeping control
and then fold change is calculated by dividing each sample by the average of the tTreg
donor values. Data represent the average of 3 donor samples, error bars represent
standard deviation. *p<.05, and **p<.005.
The Function of BiT-Upregulated Genes
While we were unable to detect mRNA levels of CD33, we sought to detect
surface protein expression via flow cytometry. BiTs showed a significant increase of
CD33 expression on Foxp3+CD25+CD4+CD3+ cells in comparison to tTregs and
iTregs (Figure 6A/B). In order to better visualize this, we next performed t-SNE analysis
of BiTs, tTregs, and iTregs for CD3, CD4, Foxp3, CD25, and CD33 (Figure 7).
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Concatenated data of 2-3 samples per cell type demonstrated that there is a distinct
separation between BiT, tTreg, and iTreg populations, with more overlap between
tTregs and iTregs than BiT (Figure 7A). We next sought to compare the prevalence of
CD33 as a marker for these donors. Our data signify a robust Foxp3+CD33+ population
in BiT that is sparse in tTregs and iTregs (Figure 7B). These data suggest that BiT
uniquely have a population of CD33+Foxp3+CD25+CD4+ cells and that BiT is different
from iTreg and tTregs.
To this end, our lab has been unable to find a marker for BiT to determine
whether BiT are a pre-existing cell type. With the discovery of CD33 on BiT with limited
expression on iTreg and tTreg populations, we sought to elucidate whether
CD33+Foxp3+ cells exist in fresh UCB versus APB. To test this, we isolated fresh
PBMCs from APB and UCB and labeled for CD3, CD4, CD8, Foxp3, and CD33. Of
interest, we found that in fresh UCB that there is a pre-existing subset of CD33+ Tregs
that does not exist in APB (Figure 8). This could suggest that the CD33+ population is
expanded in in vitro culture, since before our lab previously expanded CD25-depleted
cells. Further work will need to be performed to determine the growth of this population.
In congruence with our qPCR data, we were next able to detect the expression of
SGK1, THEMIS, and SOS1 by western blot (Figure 9). There was a slight,1.5-fold
increase in expression of SOS1 in BiT. THEMIS expression was heightened 2-fold by
BiTs in comparison to tTregs from adults. However, iTregs also elevated THEMIS
expression, greater than BiTs, which makes this protein less viable as a marker for BiT.
Lastly, we observed an interesting phenomenon with SGK1 expression. While tTregs
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and iTregs expressed SGK1, BiT donors expressed a smeared pattern of SGK1. A
smeared pattern suggests either ubiquitination or sumoylation. Both processes are posttranslational modifications. Ubiquitination flags proteins with ubiquitin for degradation
(N. Zheng & Shabek, 2017). Sumoylation is a similar process in which small
polypeptides are enzymatically attached to target proteins, modifying them by masking
binding sites or adding surfaces to the protein (Geiss-Friedlander & Melchior, 2007).
This can alter localization, activity, and stability of the flagged protein (Geiss-Friedlander
& Melchior, 2007). Both modifications are reversible, however, they achieve the same
outcome where the protein that is marked often loses functionality (Geiss-Friedlander &
Melchior, 2007; N. Zheng & Shabek, 2017). This suggests that SGK1 while upregulated

A)

Normalized to Mode

by BiT, is negatively controlled by either of these processes.
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Figure 6. CD33 Surface Expression in BiT versus APB Tregs.
Representative figure of CD33 expression in tTregs, iTregs, and BiT (A) and quantified
(B). Isotype control is a BiT donor stained with respective isotype antibodies. Data
represent the average of 2-4 donor samples, *p<.05, **p<.005, and ***p<.0005.
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Figure 7. t-SNE Plots Demonstrate BiT as Different from tTregs and iTregs.
t-SNE plots of (A) BiT (blue), iTreg (orange), and tTreg (green) concatenated donors;
n=2-3, and (B) iTreg (left), tTreg (center), and BiT (right) donors highlighting
CD3+CD4+CD25+ populations expressing Foxp3+CD33+ (blue), Foxp3+CD33(orange), or Foxp3- (green); n=2-3. Data collected via flow cytometry labeling of CD3,
CD4, CD25, Foxp3, CD96, and CD33.
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Figure 8. CD33+Foxp3+CD4+ T Cells Exist in UCB and not APB.
Fresh APB and UCB samples gated on CD3+CD4+CD25+Foxp3+ cells assessing
Foxp3 (y-axis) and CD33 (x-axis) expression. (A) Representative fresh APB (left) and
UCB (right) donors (B) Quantification of 3 donor samples, *p<.05, **p<.005, and
***p<.0005.
Calcitriol Promotes Treg/BiT Induction
Our data, along with others, demonstrated that a one-time treatment with
calcitriol upregulated Foxp3+CD25+CD4+ T cells. However, in BiT induction cultures,
our lab uses total PBMCs. We questioned from this whether calcitriol’s effect on
BiT/Treg induction was a direct effect on T cells or if another cell type, such as
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monocytes, were involved. To address this, we first assessed the function of calcitriol on
UCB monocytes and later tested the function of calcitriol as a differentiating factor for
naïve CD4 T cells.
SECTION 2: The Effect of Calcitriol on Monocytes
Monocytes are Necessary for BiT Induction
Our lab previously found that BiT induction was enhanced in the presence of
other UCB cells, rather than just stimulation of T cells alone. To determine the
population responsible for the enhancement in induction, our lab depleted various
immune cell populations and ran BiT induction cultures. To this end, our lab found that
depletion of CD14+ monocytes resulted in a significant decrease in Foxp3+CD25+
expression, identifying that monocytes are important for BiT induction (Figure 10A/B).
Along with this, it was found that endogenous TGF-β from monocytes was
important for BiT induction cultures. Depletion of CD14+ monocytes lead to decreased
Smad2/3 activation in the T cells, which are transcription factors known to be activated
during TGF-β signaling (Figure 10C/D). These data suggest that monocytes are
essential for BiT induction and are a key TGF-β producer. In concurrence with this, our
lab also has found that monocytes from both UCB and APB are able to induce Foxp3
and CD25 expression in T cells in a similar manner (data not shown). Together, these
data indicate that monocytes are a key player in BiT/Treg induction.
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Figure 9. Protein Expression of SGK-1, THEMIS, and SOS1.
(A) Western blot analysis of SGK1, THEMSI, SOS1, and Histone-H3 by BiT (left three
lanes), tTreg (center three lanes), and iTreg (right three lanes). Numbers on the left
depict kDa weight. Numbers under each lane represent normalization to their respective
Histone-H3 control and then normalized to the average of all tTreg donors. (B)
Quantification of part (A). Band intensity calculated by ImageJ software, *p<.05,
**p<.005, and ***p<.0005.
Calcitriol Promotes NRP-1 on Monocytes
My data has demonstrated that BiT induction cultures with one-time treatment of
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calcitriol at culture start leads to increased BiT induction (Figure 11 A/C). In correlation, I
have demonstrated that UCB monocytes express increased NRP-1 expression after
treatment with calcitriol (Figure 11 A/B). These data show that calcitriol upregulates
NRP-1 on monocytes, and that NRP-1 expression on day 1 correlated with increased
BiT induction on day 14 (Figure 11D).

Figure 10. Monocytes are Necessary for BiT Induction.
Total UCB or CD14 monocyte-depleted UCB were cultured in the presence of anti-CD3
and IL-2. For (A/B) cells were harvested after 14 days. For (C/D) cells were harvested
after 2 days. (A/B) Foxp3 and CD25 expression of BiT induced from total UCB (left) or
CD14 depleted UCB (right). (C/D) pSmad2/3 levels in CD4+ cells 48 hours after BiT
induction culture start in the presence (left) or absence (right) of CD14+ monocytes,
*p<.05, **p<.005. Figure adapted from (J. Lee et al., 2020).
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Figure 11. Calcitriol Promotes NRP-1 Expression on Monocytes.
(A) BiT induction after 10nM calcitriol or DMSO treatment labeled for Foxp3 and CD25
expression on Day 14 (left) and NRP-1 and CD36 on Day 1 CD14+ monocytes (right).
(B) NRP-1 expression on CD14+CD36+ monocytes from UCB 24 hours after calcitriol or
DMSO treatment. (C) Quantification of calcitriol-mediated BiT induction compared to
DMSO control. Data represent 4 donor samples, *p<.05 (D) Linear regression of Day 1
NRP-1+ monocyte expression compared to Day 14 BiT induction measured by
CD4+Foxp3+CD25+ cells.
Since our lab demonstrated that monocytes are essential for BiT induction, I
hypothesized that this upregulation of NRP-1 on UCB monocytes is a key factor for the
increase in BiT induction after calcitriol treatment. NRP-1 upregulation also correlates
with the finding that UCB monocytes were key in presenting TGF-β to T cells, as NRP-1
is able to bind both latent and active TGF-β (Glinka & Prud'homme, 2008; Glinka,
Stoilova, Mohammed, & Prud'homme, 2011). Furthermore, Stephanie Chapman, M.S.,
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a previous student in the lab also found donors that had sufficient levels of vitamin D in
their serum had elevated NRP-1 on their monocytes in comparison to those that were
deficient, along with a positive correlation between Treg and NRP-1 frequency (data not
shown). Together, these data demonstrate that the effects we see with calcitriol in vitro
are relevant to in vivo data.
NRP-1 Monocyte Effect on BiT Induction
The previous section demonstrates a correlation between NRP-1 on monocytes
and BiT induction. We sought to confirm whether there is a direct effect of NRP-1
function on BiT induction without calcitriol being present in the culture, which could skew
results. To answer this, I designed a CRISPR-Cas9 gene editing system to knock out
NRP-1. I found that THP-1, a human AML monocytic cell line, had constitutive
expression of NRP-1 (Figure 12A). After transduction, I generated a NRP-1 knockout
cell line from single clones (Figure 12B). Following cloning, I then performed a BiT
induction culture using THP-1 in place of monocytes with total CD3 T cells and IL-2 for
14 days. I hypothesized that cells cultured with NRP-1 knockouts would have reduced
BiT induction compared to the vector control. However, we saw no significant change in
BiT induction regardless of NRP-1 status (Figure 12C).
In order to discern whether day 14 was too late of a timepoint, we decided to
detect p-SMAD2/3 expression after 48 hours. Previous data suggested that p-SMAD2/3
expression is upregulated in the first few days of culture by monocytes (Figure 10C/D).
However, we also observed no difference in p-SMAD2/3 expression of cells cultured
with NRP1-/- THP-1 versus vector control (data not shown).
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Figure 12. NRP-1 Knockout in THP-1 did not change BiT induction.
(A) NRP-1 expression on THP-1 (light grey) compared to isotype control (dark grey). (B)
The purity of NRP-1 knockout THP-1 line (right) in comparison to vector control (left).
The y-axis shows expression of the mCherry surrogate marker for the CRSPR/Cas9
expression vector with NRP-1 expression on the x-axis. (C) BiT induction with vector
control THP-1 (left) or NRP-1 knockout THP-1 (right) in place of monocytes after 14
days. Total T cells were enriched from UCB and then co-cultured at a 4:1 ratio with
respective irradiated THP-1 population with IL-2 and anti-CD3.
Lastly, our lab previously demonstrated that monocytes were a key TGF-β
producer in BiT induction cultures. We hypothesized that NRP1-/- THP-1 would have
reduced active TGF-β in the culture supernatants due to the fact that NRP-1 is known to
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have the ability to bind latent TGF-β and aid in activating TGF-β. Indeed, we found that
both knockout lines had reduced active TGF-β in the culture supernatants in
comparison to the vector control (Figure 13). However, there was no difference in total
TGF-β in the culture system, which may explain why we failed to observe any significant
difference in BiT induction or p-SMAD2/3 activation (Figure 12 and 13).

Figure 13. TGF-β Production by Transduced THP-1 Lines.
Culture supernatants of transduced THP-1 lines were collected after 24 hours and
added to MFB-F11 cells. After 48 hours, these cumulative supernatants were treated
with PNPP in alkaline conditions. If active TGF-β was present in the culture, then color
change was assessed via a plate reader at 450nm. As a control, THP-1 supernatants
were first acid-treated prior to addition to MFB-F11 cells to cleave latent-TGF-β and
demonstrate total TGF-β in the culture. Data points depict two biological replicates per
cell line, *p<.05.
IFN-β Effect on Monocyte NRP-1 and VEGF Chemotaxis
Calcitriol increases BiT induction and expression of NRP-1 by monocytes.
Conversely, IFN-β treatment significantly reduces Treg induction (Srivastava, Koch,
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Pepper, & Campbell, 2014). Thus, I hypothesized that IFN-β would also reduce
monocytic NRP-1. To address this, I assessed NRP-1 expression on both purified
monocytes and monocytes in total cord blood cultures in vitro overnight in the presence
or absence of IFN-β. We purified nucleated cell fractions from UCB, then treated cells
with IFN-β. When monocytes were cultured in the presence of IFN-β, both as total
PBMCs and enriched for CD14+ cells enriched and as total PBMCs, we observed a
significant reduction in the level and frequency of NRP-1 expression by CD14+
monocytes demonstrating that IFN-β directly works on monocytes (Figure 14).
While we failed to demonstrate NRP-1 as a necessary factor for BiT induction,
NRP-1 can bind multiple ligands. Another such ligand is vascular endothelial growth
factor (VEGF). VEGF plays a pivotal role in organogenesis in embryos and
angiogenesis in adults. VEGF promotes migration of monocytes which supports
angiogenesis by producing growth factors. Since NRP-1 is a co-receptor for VEGF,
which induces chemotaxis of monocytes, we next tested if IFN-β reduced monocyte
chemotaxis towards VEGF. To address this, we performed a monocyte transwell
migration assay to detect VEGF-induced migration of untreated monocytes in
comparison to IFN-β treated monocytes to the bottom of the well overnight. As
hypothesized, IFN-β treatment significantly reduced the migration of VEGF-exposed
monocytes, suggesting that monocyte’s chemotactic response to VEGF is reduced by
IFN-β (Figure 15A).
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Purified CD14+

Figure 14. IFN-β Reduces NRP-1 Expression on Monocytes.
Purified UCB monocytes cultured in the presence or absence of 10ng/ml IFN-β
overnight. (A) Representative figure depicting monocyte expression of NRP-1 cultured
with other UCB cells in the presence or absence of 10ng/ml IFN-β overnight. (B)
Quantification of NRP-1 percent change and MFI shift gated on monocytes (CD14+),
****p<0.0005 and **p<0.005, respectively. (C) Representative Figure of NRP-1 MFI shift
on purified monocytes. (D) Quantification of NRP-1 percent change and MFI on purified
monocytes, **p<0.005 and ***p<0.001, respectively. Data represent 4-5 donors. Isotype
controls represent IFN-β treated monocytes labeled with isotype antibodies.
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Figure 15. Reduced NRP-1 Resulted in Decreased Migration towards VEGF for
IFN-β Treated, NRP1-/- cells, and anti-NRP-1 Treated Cells.
(A) Transwell migration fold change for IFN-β treated cells in the presence or absence
of VEGF. Cell numbers are normalized to their respective non-VEGF control normalized
to 1. **p<0.005. (B) Transwell migration fold change induced by VEGF. Relative number
of the migrated cells with VEGF for each cell line is shown (number of THP-1 cells that
migrated without VEGF are normalized to 1); * p<0.05 and **p<0.0001. (C) Transwell
migration fold change induced by VEGF after primary monocytes were incubated with
anti-NRP-1 neutralizing antibody or isotype control, number of monocytes migrated are
normalized to respective isotype control, with isotype normalized to 1; *p<.05, **p<.005,
***p<.0005, and ****p<.0001.
If reduced monocyte chemotaxis in response to VEGF is caused by the reduction of
NRP-1 expression, then monocytes that do not express NRP-1 would fail to respond to
VEGF. To test this hypothesis, we utilized the NRP-1 knockout THP-1 cell lines
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described above. As observed for untreated primary monocytes, VEGF induced
chemotaxis of THP-1 cells transduced with Cas9 alone. In contrast, both NRP-1
knockout clones had significantly reduced migration in response to VEGF, similar to
IFN-β treated monocytes (Figure 15B), demonstrating that expression of NRP-1 plays a
critical role in VEGF-induced chemotaxis of monocytes. Finally, to demonstrate the role
of NRP-1 on VEGF chemotaxis for primary monocytes, I repeated the transwell assay
after pre-incubating primary monocytes with an anti-NRP-1 neutralizing antibody. As
expected, blocking NRP-1 lead to reduced chemotaxis towards VEGF in a dosedependent trend (Figure 15C). Together, these data demonstrate that IFN-β has a direct
effect on reducing monocyte chemotaxis toward a VEGF enriched environment via
reduction of NRP-1
SECTION 3: The Effect of Calcitriol on T cells
Calcitriol Promotes a Unique Cytokine Profile
It is well appreciated that calcitriol is a key immunomodulatory molecule that has
pleiotropic effects on immune cells, as discussed in Chapter 1. However, the effect of
calcitriol on naïve CD4 T cell differentiation is not well defined. Our previous data along
with others have shown that calcitriol treatment of CD4 T cells leads to a reduction in
Th1 and Th9 cytokines and an upregulation in Th2 cytokines, while other reports show
an increase in Treg induction (Figure 26C)(Cantorna et al., 2008; Mahon et al., 2003;
Mattner et al., 2000; Nashold et al., 2001; Rausch-Fan et al., 2002; Sloka et al., 2011;
Staeva-Vieira & Freedman, 2002; Takami et al., 2015). Therefore, we sought to
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determine the cytokine profile of calcitriol-treated T cells. To do this, we treated naïve
CD4 T cells isolated from human PBMCs with plate-bound anti-CD3/anti-CD28
stimulation in the presence of IL-2 for five days and then measured culture supernatants
for T helper cytokines using a cytometric bead array (Figure 16). Coinciding with other
studies concluding an increase in Th2 cells, we observed a significant increase in IL-13
production (Figure 16A). However, we observed no detectable levels of IL-4 and no
significant change in IL-5 production compared to control (data not shown and Figure
16C). Instead, we report a striking elevation in IL-6 production (Figure 16B). In
agreement with others, we also observed a decrease in IFN-γ and IL-22 production
(Figure 16C). However, in contrast to the literature, we detected no significant changes
in TNF-α or IL-10 (data not shown & 16C) (Di Rosa, Malaguarnera, Nicoletti, &
Malaguarnera, 2011; Joshi et al., 2011). To our surprise, we also found a significant
increase in macrophage colony stimulating factor (M-CSF) after calcitriol treatment
(Figure 16D).
Our previous findings indicate that calcitriol inhibits AhR signaling which is
important for T cell differentiation into Th9 cells and is also known to skew towards a
Th1 dominant immune response (Negishi et al., 2005; Takami et al., 2015). However,
when we tested whether AhR inhibition was necessary for this cytokine profile, utilizing
a chemical antagonist specific to AhR (CH223191), we did not see any significant
changes in cytokine production in comparison to control except for IFN-γ reduction
(Figure 17). This suggests that other transcription factor(s) are important for the
phenotype induced by calcitriol, and not directly from inhibition of AhR.
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Figure 16. Calcitriol Promotes IL-13 and IL-6 Production by Human Naïve CD4 T
Cells.
The effect of calcitriol on (A) IL-13, (B) IL-6, (C) IFN-γ, IL-5, IL-10, IL-22 and (D) M-CSF.
Human naïve CD4 T cells enriched from adult PBMCs were stimulated under neutral
conditions with IL-2 in the presence (squares) or absence (DMSO; circles) of 10nM
calcitriol. Secreted cytokine concentrations were determined by cytometric bead array.
Data represent the average of 7-9 donor samples, error bars represent standard
deviation. *p<.05, **p<.005, and ***p<.0005.
Calcitriol Promotes CTLA-4 and PD-L1 Expression on T Cells
With the evidence that vitamin D is protective against autoimmunity and helps
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alleviate symptoms, we hypothesized that calcitriol will upregulate checkpoint molecules
to reduce inflammation. In line with our hypothesis, recent papers found that total CTLA4 expression was upregulated after calcitriol treatment (Jeffery et al., 2009; Jeffery et
al., 2015; Kickler, Ni Choileain, Williams, Richards, & Astier, 2012; Spanier et al., 2020).
To determine if our model produced results consistent with the literature, we
treated naïve CD4 T cells with or without (DMSO) calcitriol in the presence of IL-2 on
plate-bound anti-CD3 and anti-CD28 stimulation for 3-5 days and then labeled for
extracellular and intracellular CTLA-4. We observed that calcitriol treatment upregulated
surface CTLA-4 MFI and expression on CD4 T cells in comparison to the DMSO control
(Figure 18A). The percent of cells expressing CTLA-4 on their surface was consistently
higher than DMSO treated cells over time, where DMSO treated T cells began to lose
expression of surface CTLA-4 after day 4 while calcitriol-treated T cells maintained
heightened expression (Figure 18B). This observation is unique in the fact that the
literature only detected total CTLA-4 instead of distinguishing between surface and
intracellular expression. In congruence with the literature, we found total CTLA-4 to be
upregulated in T cells after calcitriol treatment (Figure 18C), in which all cells were
positive for CTLA-4 expression, with a majority of cells expressing both surface and
intracellular CTLA-4. Further, MFI of both intracellular and extracellular CTLA-4 was
elevated after calcitriol treatment (Figure 18D). Here, we demonstrate that CTLA-4
expression is drastically enhanced extracellularly after calcitriol treatment, while also
maintaining elevated intracellular CTLA-4 expression in comparison to DMSO-treated
control cells. To determine whether this upregulation of CTLA-4 was due to a change in
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transcription, we performed qPCR. We also observed that CTLA-4 mRNA was elevated
after calcitriol treatment (Figure 18E). Together, these data demonstrate that calcitriol
has a direct effect on CTLA-4 upregulation, both at the mRNA and protein levels in
naïve CD4 T cells which leads to increased CTLA-4 surface expression on these cells.

Figure 17. Inhibition of AhR does not Control Calcitriol-Treated Cell Cytokine
Profile.
Calcitriol and AhR inhibitor (CH223191) effect on (A) IL-13, (B) IL-6, (C) IFN-γ and (D)
TNF-α cytokine expression by naïve CD4 T cells stimulated by plate-bound anti-CD3
and anti-CD28 with IL-2 for 5 days in the presence of DMSO (circles), calcitriol
(squares), or CH223191 (triangles). Data represent 3 donor samples, *p<.05 and
**p<.005.
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Figure 18. The Effect of Calcitriol on CTLA-4 Expression.
Surface CTLA-4 expression day 4 post-treatment on unstimulated, DMSO, and
calcitriol-treated CD4 T cells, isotype control are calcitriol-treated cells labeled with
respective isotype antibodies. (A) representative donor and (B) quantification on days 35, n=4. (C) CTLA-4 extra- and intracellular co-labeling. (D) MFI expression, n=4-5. (E)
Relative CTLA-4 mRNA expression of unstimulated or stimulated cells with or without
calcitriol treatment normalized to 18SrRNA (housekeeping) and then to the respective
Day 0 control, n=3. Human naïve CD4 T cells from adult PBMCs were stimulated under
neutral conditions with IL-2 in the presence or absence of calcitriol and labeled for flow
cytometry days 3-5 post-treatment or isolated for RNA day 4 post-treatment. Data
represent the average of 3-5 donor samples, error bars represent standard deviation.
*p<.05, **p<.005, and ***p<.0005.
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Since it is known that calcitriol aids in preventing autoimmunity and we observed
an increase in CTLA-4 expression, we hypothesized that calcitriol would also upregulate
the PD-1/PD-L1 axis on CD4 T cells. To test this, we used the same culturing method
as in Figure 18. First, we measured PD-1 expression after harvesting cells on day 4
post-treatment and performed flow cytometry for surface expression of PD-1 and
observed no significant difference in expression on CD4 T cells (Figure 19B, right).
Next, we looked at a ligand for PD-1, PD-L1. In contrast to PD-1, we observed an
increase in PD-L1 MFI and expression on the surface of CD4 T cells after calcitriol
treatment on both 3- and 5-days post-treatment (Figure 19A/B). A recent report
suggests that T cells have the ability to co-express multiple immune checkpoint
molecules, and it is already known that both CTLA-4 and PD-L1 signaling is important
for Treg function so we hypothesized that both pathways would be upregulated after
calcitriol treatment (Baitsch et al., 2012). To determine if calcitriol treatment coupregulates PD-L1 and CTLA-4 expression on human CD4 T cells, after 4 days we
labeled cells for surface expression of PD-L1 and CTLA-4. We found that calcitriol
treatment lead to a robust double positive population of both PD-L1 and CTLA-4, with
few cells expressing only one checkpoint molecule in comparison to DMSO treated T
cells (Figure 19C/D). These data demonstrate that calcitriol upregulates both CTLA-4
and PD-L1 expression on the surface of naïve CD4 T cells in comparison to DMSOtreated controls.
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Figure 19. The Effect of Calcitriol on PD-L1 Expression.
Representative donor showing PD-L1 expression on unstimulated cells, DMSO treated
and calcitriol-treated CD4 T cells after 5 days. (B) Quantification on day 5 for both mean
fluorescence intensity (MFI) and percent positive cells. (C) Representative donor and
(D) quantification displaying double positive phenotype for PD-L1 and CTLA-4 4 days
after calcitriol treatment. Human naïve CD4 T cells from adult PBMCs were stimulated
under neutral conditions with IL-2 in the presence or absence of calcitriol and labeled for
flow cytometry days 3-5 post-treatment. Data represent the average of 3 or more donor
samples, error bars represent standard deviation. *p<.05, **p<.005, and ***p<.0005.
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Intrinsic and Extrinsic Suppression of the Immune System via CTLA-4
CTLA-4 has the ability to suppress in both an intrinsic and extrinsic manner
(Bour-Jordan et al., 2011). Intrinsically, CTLA-4 competes with CD28 co-stimulation and
leads to inhibition of IL-2 production, proliferation, and promotes cellular anergy.
Extrinsically, CTLA-4 is able to suppress neighboring cells that do not express CTLA-4.
One mechanism for this is transendocytosis, where CTLA-4 is able to remove CD80
and CD86 from the surface APCs and internalize them into the host cell (Qureshi et al.,
2011). This reduces the bio-available pool of CD80 and CD86 to stimulate neighboring
cells. Previous papers have demonstrated that calcitriol-treated T cells have the ability
to suppress responder T cells in a suppression assay in a CTLA-4 dependent manner
(Jeffery et al., 2009; Kickler et al., 2012). Further, one paper has demonstrated that
calcitriol-treated T cells also have the ability to perform transendocytosis (Jeffery et al.,
2015). However, it has yet to be elucidated whether CTLA-4 is acting intrinsically on the
calcitriol-treated T cells. To address this, we expanded calcitriol-treated T cells for 4
days before co-culturing with naïve responder T cells and antigen presenting cells
(APCs) for 6 days. To determine the proliferation of both responders and calcitrioltreated cells, we stained responders with CFSE and calcitriol-treated T cells with CTV.
Indeed, we observed that calcitriol-treated T cells had potent suppressive capability
over responder T cells in a dose dependent manner (Figure 20A/B). Further, we found
that CTLA-4 did intrinsically suppress proliferation of calcitriol-treated T cells in
comparison to DMSO control cells (Figure 20C/D). We demonstrate here that calcitrioltreated T cells proliferated at a slower rate than DMSO treated cells.
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To determine if this reduced proliferation was CTLA-4 dependent, we repeated
the assay using a neutralizing antibody against CTLA-4. We found calcitriol-treated T
cell proliferation is restored after treatment with anti-CTLA-4 (Figure 20C/D). For both
responders and calcitriol-treated cells, anti-PD-L1 had only a marginal impact on
suppression of proliferation (data not shown). These data demonstrate that calcitriol
promotes cells to have a suppressive capacity, while also upregulating functional CTLA4 that intrinsically suppresses the proliferation of cells that are treated with calcitriol,
where the increase of PD-L1 does not have an effect on this model.
Calcitriol-Mediated Inhibition of AhR Controls Surface CTLA-4 Expression.
While elevated expression of total CTLA-4 has been reported after calcitriol
treatment in CD4 T cells, a mechanism has yet to be determined for this upregulation.
Our previous study demonstrated that calcitriol inhibits the activation and expression of
AhR. AhR is a transcription factor with pleiotropic roles in T cell differentiation and
expression of cytokines and surface antigens in response to environmental stimuli. We
hypothesized that calcitriol-mediated inhibition of AhR leads to the increase in CTLA-4
expression. To test this, we compared CTLA-4 and PD-L1 expression after calcitriol
treatment along with using an AhR agonist, pyocyanin (Figure 21). We demonstrated
that the AhR agonist reduced CTLA-4 expression on the surface of CD4 T cells, while
calcitriol upregulated CTLA-4 expression and that calcitriol treatment could reverse the
effects of pyocyanin (Figure 21A/C). To investigate further, we attempted to knock down
AhR in T cells using siRNA. However, transfection conditions lead to a lack in CTLA-4
surface expression and thus we could not measure the effect of AhR loss.
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We further hypothesized that calcitriol has a direct effect on CTLA-4 transcription.
It is known that the turnover rate of CTLA-4 protein traditionally is linked to the rate of
transcription, thus suggesting that the observed heightened transcription and protein
expression of CTLA-4 (Figure 18 A/C/E) could be a direct effect from calcitriol (Valk,
Rudd, & Schneider, 2008). To begin to answer this question, we analyzed the CTLA-4
promoter for VDRE binding sites. We found seven potential VDRE on the CTLA-4
promoter upstream of the transcription start site, suggesting that calcitriol may directly
control CTLA-4 transcription (Figure 22). Further assays will need to be performed to
determine the functionality of these VDRE.
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Figure 20. Calcitriol-Treated Cells Suppress Responder T cells and are
Intrinsically Suppressed by CTLA-4.
Representative sample of suppression of proliferation of responder T cells (CFSE) by
calcitriol treated cells (grey) or DMSO-treated Cells (white) (A) and (B) quantified at 1
“suppressor” to 8 responder ratio between three donors. (C/D) Proliferation of calcitrioltreated or DMSO-treated cells (CTV) in the context of a suppression assay treated with
anti-CTLA-4 or the respective isotype, p<.05.
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Figure 21. Calcitriol Overcomes AhR Agonist, Pyocyanin, effect on CTLA-4 and
PD-L1.
Quantification of (A) surface CTLA-4 percentage and (B) surface PD-L1 percentage on
T cells after treatment with DMSO, calcitriol, pyocyanin (AhR inhibitor), and cotreatment of calcitriol and pyocyanin. (C) Representative donor flow plot depicting coexpression of PD-L1 and CTLA-4. Human naïve CD4 T cells from adult PBMCs were
stimulated under neutral conditions with IL-2 in the presence or absence of calcitriol and
labeled for flow cytometry 4 days post-treatment. Data represent the average of 2-3
donor samples, error bars represent standard deviation. *p<.05, **p<.005, and
***p<.0005
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cccttaaggtatcaactatgtttttgttttgtcatcattcaatcctaagtgcacagaattccgggcatattacaggttccccatga
atgtttctttctttattaaaatgtatgaaaactctccagatttaaggaaggtcctcaatgtttcaaattctttttgttagatcattggtcc
tgtctacagctgtcacaaatttaaggactctggttatatttaatcttcacttttgaattttctgcttgaaaaatttgtattagaaaaaa
aagtctatccttttatggacggctctaatctcttgaatcatttgggttggcttttctttggaccttcttcaactctgttttgtctctgttga
gttaaggcttttaagaacacctgaattctttccttctgcaaaaccagaggcagcttcttttccgcctattttcagtttatttcttgtga
ttttagtttttttctcttaaccaaatgctaaatggatttaggagaaataaacttatttgtaaagctgtcaagggaccattagaagg
atggtgcttcacagatagaatacagtttttattaatgatgcctagacaaatcctgccattagcccaagggctcagaaagttag
cagcctagtagttttggagttgtcaatgaaatgaattggactggatggttaaggatgcccagaagattgaataaaattggga
tttaggaggacccttgtactccaggaaattctccaagtctccacttagttatccagatcctcaaagtgaacatgaagcttcag
tttcaaattgaatacattttccatccatggattggcttgttttgttcagttgagtgcttgaggttgtcttttcgacgtaacagctaaa
cccacggcttcctttctcgtaaaaccaaaacaaaaaggctttctattcaagtgccttctgtgtgtgcacatgtgtaatacatatc
tgggatcaaagctatctatataaagtccttgattctgtgtgggttcAAACACATTTCAAAGCTTCAGGATCC
TGAAAGGTTTTGCTCTACTTCCTGAAGACCTGAACACCGCTCCCATAAAGCCATGG
CTTGCCTTGGATTTCAGCG
Figure 22. The Human CTLA-4 Promoter has Seven VDRE Sites.
Sequence range of -1000 to 100 of the human CTLA-4 promoter. Capitalized letters are
upstream of the transcription start site. Bolded sequences are VDRE segments, all with
p<0.001.

CHAPTER FOUR: DISCUSSION
Summary of Data
We first sought to determine whether cord blood derived Tregs, BiTs, were
genetically distinct from iTregs and tTregs. Data obtained previously in our lab
demonstrated that BiTs had a unique cytokine profile in comparison to tTregs (Figure 2)
(J. Lee et al., 2020). In this dissertation work, we examined the genetic profile of these
cells by performing RNA-seq. We determined that indeed, BiTs are a unique subset of T
cells, where they express unique markers while also expressing various markers from
all T helper cell lineages (Figures 4-9). Of interest, BiTs have Foxp3 regulated similar to
iTregs or pTregs, rather than tTregs, where the CNS2 promoter region is
hypermethylated, suggesting a plasticity of these cells (Figure 3). We next examined
BiT upregulated genes and determined that SGK1 and CD33 were potential markers for
these cells, with SGK1 showing evidence of post-translational modification only in BiTs
(Figures 7-9).
Previous data performed by us and others demonstrated that calcitriol promotes
Treg induction (Gorman et al., 2007; Jeffery et al., 2009; Nashold et al., 2013; Penna et
al., 2005; Prietl et al., 2010). We found in congruence with these results that calcitriol
promoted BiT induction. However, in BiT induction cultures there are multiple cell types
present. We next sought to determine whether calcitriol acted directly on T cells to
promote BiT induction or if the manner was indirect through another cell type. We
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decided to investigate monocytes because our lab previously found that monocytes
were necessary to aid in BiT induction (Figure 10).
First, we investigated the effect on monocytes. We found that calcitriol
upregulated NRP-1 expression on monocytes (Figure 11). It is known that NRP-1 is
able to bind both latent and active TGF-β, while also having the role of being able to
activate TGF-β. We hypothesized that this upregulation of NRP-1 would aid in BiT
induction due to an increased pool of active TGF-β. However, while there was a direct
correlation between NRP-1 expression and BiT induction, our knockout experiments did
not yield any significant difference in BiT induction (Figure 12). However, since this was
only using the THP-1 cell line, future experiments should be performed to confirm the
same is true with primary monocytes. The only difference we observed was that NRP-1
had an increased effect on active TGF-β in the culture, but the total TGF-β pool was
unchanged (Figure 13).
We and others have found that IFN-β decreases Treg induction and this held true
for BiTs. When we looked at the effect of IFN-β on monocytes, we observed a complete
loss of NRP-1 expression overnight (Figure 14). It is known that NRP-1 can respond to
VEGF signaling in a chemotactic fashion (Dejda et al., 2014; P. Lee et al., 2002). Since
IFN-β is known to reduce angiogenesis and VEGF is essential for angiogenesis and the
recruitment of monocytes for angiogenesis, we hypothesized that the ablation of NRP-1
expression would lead to reduced monocytes chemotaxis (Hallene et al., 2006; Heil et
al., 2000; Hong et al., 2005; K. J. Kim et al., 1993; Takano et al., 2014; Yang et al.,
2003; Zeiher et al., 1995; H. Zheng et al., 2011). Indeed, we found a direct correlation
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between NRP-1 expression, IFN-β treatment, and chemotaxis towards VEGF (Figure
15).
Finally, we decided to investigate the direct effect of calcitriol on T cells. Previous
data by us and the literature stated that calcitriol promoted BiT/Treg induction, along
with differentiation away from Th1 and towards a Th2 lineage (Figure17) (Cantorna et
al., 2008; Daniel et al., 2008; Jeffery et al., 2009). However, we found that upon
stimulation of naïve CD4 T cells that calcitriol promoted differentiation of a unique
subset of T cells. These T cells expressed suppressive markers similar to Tregs, CTLA4 and PD-L1, however they produced cytokines such as IL-6, IL-13, and M-CSF
(Figures 16-19). Even though these cells were not Tregs, they were functionally
suppressive (Figure 20). The CTLA-4 expression was found to further have an intrinsic
effect on suppressing proliferation of T cells (Figure 21).
In summary, we found that BiTs are a unique T cell subset that differs from
previously defined Tregs. Calcitriol, which promotes BiT induction, was found to
promote the expression of checkpoint molecules on the surface of naïve CD4 T cells.
These checkpoint molecules, namely CTLA-4, had an intrinsic suppressive effect, thus
bolstering immune suppression. Lastly, while NRP-1 was not necessary for BiT
induction, we found that calcitriol upregulated NRP-1 and IFN-β downregulated NRP-1
on monocytes. This robust downregulation of NRP-1 is a novel mechanism by which
NRP-1 could inhibit angiogenesis.
BiTs are a Unique Cell Type
Our lab previously described that BiTs upon restimulation expressed GM-CSF
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and IL-8, cytokines that stimulate macrophages and neutrophils, respectively (Figure 2)
(J. Lee et al., 2020). These cytokines were not produced by Tregs harvested from APB
which suggested that BiT were not classical Tregs even though they expressed Foxp3
and CD25 (Figure 2). While there are different types of Tregs, there is a lack of
knowledge in the field of markers that distinguish them from each other (Curotto de
Lafaille et al., 2004; Shevach & Thornton, 2014). Instead, currently the only definitive
way of determining tTregs, pTregs, and iTregs from each other is the methylation status
of the foxp3 promoter (Kitagawa et al., 2013; Lal et al., 2009; Minskaia et al., 2018;
Morikawa et al., 2014). The CNS2 region confers stability of Foxp3 expression when it
is de-methylated, a hallmark of tTregs (Morikawa et al., 2014; Someya et al., 2017; Y.
Zheng et al., 2010). Our data show that BiT are more similar to iTregs and effector T
cells, where the CNS2 region is methylated, suggesting plasticity in these cells. Our lab
plans to further test methylation status on the CNS1 region in BiT, since iTregs and
pTregs have a hypomethylated CNS1, while tTregs do not. This could further elucidate
a mechanism for Foxp3 regulation in BiTs.
In order to determine whether BiTs are a unique T cell subset or if they had any
distinguishing markers, we performed RNA-seq. From this, we found there are 2016
DEGs between effector T cells, BiT, tTregs, and iTregs. Our data suggests that BiT do
not fall into any previously defined Th subsets, as they lack uniform upregulation of
genes from any of these subsets (Figure 4). Next, we investigated whether there were
any potential markers upregulated by BiT from the list of DEGs. There was one
candidate gene that is known to be expressed on the surface of cells, CD33 (SIGLEC
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3). CD33 has previously been recognized as a myeloid-specific marker that acts as an
inhibitory receptor via its ITIM domain (Paul, Taylor, Stansbury, & McVicar, 2000).
However, it has been reported that human T and NK cells can express splice isoforms
of CD33 (Hernández-Caselles et al., 2006). The previous report suggests that CD33
can aid in inhibiting cytotoxic function in NK cells, however there have been no
proposed functions for CD33 in T cells (Hernández-Caselles et al., 2006). Our data
demonstrate that tTregs and iTregs do not express CD33, but a population of cells from
BiT induction cultures do (Figures 6 and 7). Further experiments will need to be
performed to determine which isoform of CD33 are expressed by these cells, if the
ligand binding domain is intact, and whether it has a functional role in T cells. Our data
also show a Foxp3+CD33+CD4+ population in fresh UCB that does not exist in fresh
APB, further studies will have to be performed on this pre-existing population to define if
these are naturally arising BiT (Figure 8).
Novel Upregulated Genes in BiTs and their Functional Relevance on Foxp3
Expression
Besides CD33 as a potential surface marker for BiT, we also examined three
intracellular proteins: SOCS1, THEMIS, and SGK1. While BiT had upregulated SOCS1
and THEMIS on the mRNA level in comparison to tTregs and iTregs, on the protein
level SOCS1 was moderately upregulated, and THEMIS was only upregulated in
comparison to tTregs and expressed less than iTregs. However, we observed a striking
phenotype when detecting SGK1 expression in BiTs. Unlike in iTregs and tTregs, SGK1
in BiTs were post-translationally modified as demonstrated by a smear on western blot
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Figure 9). Post translational modifications, such as ubiquitination and sumoylation, add
weight to their target protein, which is what leads to this smear. These modifications can
alter the localization, activity, and stability of the flagged protein leading to loss of
functionality or degradation of the protein (Geiss-Friedlander & Melchior, 2007; N.
Zheng & Shabek, 2017). This suggests that while SGK1 is upregulated by BiT, it is also
negatively controlled by potentially one of these processes. Of interest, SGK1 has been
reported as a mechanism for control of the Th17-Treg axis (C. Wu et al., 2018). The
mechanism involves phosphorylated SGK1 binding and sequestering Foxo1 from
entering the nucleus. This downstream leads to the inhibition of Foxp3 transcription and
promotes IL-23R transcription, allowing for Th17 differentiation while inhibiting Treg
differentiation (C. Wu et al., 2018). However, another article defines that SGK1 can be
ubiquitinated by a complex of Rictor and Cullin-1, which leads to degradation of SGK1
(Gao et al., 2010). Of note, one of the DEGs upregulated by BiT is Rictor, while Cullin1
counts are relatively equal among all samples (data not shown). Further, another
member in the lab recently demonstrated that restimulating BiTs in the presence of
differentiating cytokines does not differentiate BiTs into other T cell subsets, and Foxp3
expression is similar among all treatments suggesting that Foxp3 is stable in these
samples regardless of CNS2 methylation status (data not shown). This also coincides
with previous data that Foxp3 expression remains stable in BiT for months (Figure 1).
These data suggest that post-translational modification of SGK1 in BiT could inhibit its
ability to sequester Foxo1, leading to subsequent stable expression of Foxp3. However,
further experiments should be performed to determine whether BiT can be induced from
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already differentiated cells, such as Th1 or Th2 cells which could uncover whether naïve
T cells are necessary for this phenotype.
Implications of these Data: Foxp3 Control in BiT
It is well appreciated that understanding tolerance in fetuses and neonates is
important, as the tolerance acquired as a fetus and in early life can last a lifetime
(Billingham et al., 1953; Maloney et al., 1999; Mold et al., 2008). In these data, we
define BiT, a Treg unique from other previously defined Treg subsets. Our data identify
CD33 as a candidate surface marker because we observed CD33 in fresh UCB and not
APB on Foxp3+CD4+ T cells. Since CD33 is a surface protein, CD33 expression will
allow for tracking of this subset and further phenotypic testing (Figures 6-8). Previously,
without knowledge of a marker for BiT, we were unable to bring our studies into a
mouse model. With CD33 in mind, our lab can continue to look for a similar marker in
mice, which could allow for in utero and in vivo studies, something we have been limited
from performing with human-only samples.
With the existence of a surface marker for BiT, our lab can begin to address
questions pertaining to the persistence of BiT. We know that BiT were not detectable in
healthy adult peripheral blood (Figure 8) in contrast to UCB and NICU blood. This
suggests to us that this cell type only persists at a young age, but we have not
assessed whether BiT arise during immune dysregulation or during pregnancy in
mothers. However, it is known that T cells from UCB and neonatal PBMCs have a
higher propensity to develop into Tregs (Figure 1) (Burlingham et al., 1998; Mackroth et
al., 2011; A. K. Simon, Hollander, & McMichael, 2015; Takahata et al., 2004). This

84
propensity rapidly dwindles during the first 36 months of life (Olin et al., 2018; Shearer
et al., 2003; Zhao et al., 2007). Preliminary experiments performed by Alex Nelson,
M.S., and Christina Cunha in our lab assessed the ability to induce BiT from adult naïve
T cells. Nelson found that depletion of granulocytes allowed for BiT induction, while
conversely, Cunha found that adding adult T cells to a UCB culture inhibited BiT
induction. Both experiments provide rationale that factors from adult immune cells inhibit
BiT induction, however more experiments need to be performed to determine which
factor(s) are responsible and why.
Vaccination in utero and in early life has posed difficulties in the field due to
suboptimal immune responses toward the vaccine, in which a tolerant and Treg-rich
environment have been named as culprits (Ndure & Flanagan, 2014). Understanding
how to control or manipulate this tolerance could allow for designing co-treatments with
vaccinations to boost fetal and neonatal responses and thus protecting them from viral
infections (Ndure & Flanagan, 2014). However, while it is well known that T cells from
UCB have an increased propensity to become Tregs, the mechanism for this is not well
understood (C. C. Chang et al., 2005; de Roock et al., 2011; Dirix et al., 2013; J. Lee et
al., 2020; Takahata et al., 2004; Torelli et al., 2012). Our data propose a model for
Foxp3 regulation in BiT involving post-translational modification of SGK1 (Figure 23).
Further studies will need to be performed to determine whether the mechanism is
sumoylation or ubiquitination, and whether the previously described Rictor-Cullin1
complex is present in BiT (Gao et al., 2010). Uncovering and understanding this
mechanism for Foxp3 control can help uncover why T cells from UCB have a higher
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propensity to become Tregs. In the context of vaccinations, manipulating this proposed
system by administering a Rictor inhibitor to inhibit Foxp3 stability could lead to a
heightened response to vaccines. Further in vivo testing would need to be performed to
test this model.

Figure 23. Proposed Model for Foxp3 Stability in BiT.
Figure depicting a proposed model for Foxp3 stability in BiT. This model involves the
presence of Rictor and Cullin-1 complexing and poly-ubiquitinating SGK-1. This poly-Ub
sequesters SGK1 away from FoxO1, allowing for FoxO1 to translocate into the nucleus
and promote transcription of Foxp3.
NRP-1 Contributes to a Larger Pool of Active TGF-β but is not Necessary for BiT
Induction
Our lab previously described the necessity for monocytes in BiT induction
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cultures and that monocyte-derived TGF-β was important for this effect (Figure 10) (J.
Lee et al., 2020). Jessica found that monocytes were essential for TGF-β production by
depleting different non-T cell populations from UCB and performing BiT induction
cultures. The only cultures she found that had reduced BiT induction were CD14+
monocytes, which reduced BiT induction by approximately 50%. She then looked at
pSMAD2/3 induction in the presence or absence of CD14+ monocytes, which is
indicative of TGF-β signaling, and found that this was reduced by roughly ~40% when
there were no monocytes in the culture (Figure 10). We found that calcitriol upregulated
NRP-1 expression on monocytes and that calcitriol promoted increased BiT induction
(Figure 11). It has been previously established that NRP-1 is able to bind both latent
and active TGF-β, and also have the functionality to activate TGF-β (Glinka &
Prud'homme, 2008; Glinka et al., 2011). We hypothesized that this upregulation of NRP1 would aid in BiT induction due to an increased pool of active TGF-β. However, while
there was a direct correlation between NRP-1 expression and BiT induction, our NRP-1
knockout experiments did not yield any significant difference in BiT induction (Figure
12). The only difference we observed was that deletion of NRP-1 reduced the
concentration of active TGF-β in the culture, but the total TGF-β pool was unchanged
(Figure 13). These data suggest to us that since the total TGF-β pool was unchanged,
the presence of NRP-1 is not a determining factor in BiT induction and further studies
must be performed to determine how calcitriol promotes BiT induction in the context of
monocytes.
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Novel Discovery that IFN-β Controls NRP-1 Expression
Angiogenesis is important for fetal development because proper blood flow is
necessary for both the health of the pregnancy and for the fetus’ development by aiding
in nutrient transfer from the mother to the fetus (Mayhew et al., 2004; Reynolds et al.,
2006). When this blood flow is restricted there is decreased fetal growth, vascularity,
and an increased probability for compromised pregnancies (Crivellato, 2011; Mayhew et
al., 2004; Reynolds et al., 2006). Angiogenic factors, such as VEGF, play a role in
organogenesis by signaling to organs to instruct patterning and morphogenesis
(Crivellato, 2011). With how crucial angiogenesis is for fetal development, it is important
to recognize mechanisms which can bolster or restrict angiogenesis. Our studies
focused primarily on effects that could impede VEGF-mediated chemotaxis of
monocytes. It is accepted that VEGF plays a pivotal role in angiogenesis by acting as a
chemotactic factor for endothelial cells and monocytes (Heil et al., 2000; Hong et al.,
2005). One receptor known to respond to VEGF signaling in a chemotactic fashion is
NRP-1 (Hallene et al., 2006; Heil et al., 2000; Hong et al., 2005; K. J. Kim et al., 1993;
Takano et al., 2014; Yang et al., 2003; Zeiher et al., 1995; H. Zheng et al., 2011).
Further, it is also known that IFN-β is a potent inhibitor of angiogenesis through multiple
mechanisms (Hallene et al., 2006; K. J. Kim et al., 1993; Takano et al., 2014; Yang et
al., 2003; Zeiher et al., 1995; H. Zheng et al., 2011). However, our data report a novel
mechanism for IFN-β mediated downregulation of NRP-1 which leads to a subsequent
significant reduction in chemotaxis towards a VEGF enriched environment (Figures 13,
14, and 15).
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Implications of these Data: A Novel Mechanism for IFN-β Mediated Reduction in
Angiogenesis
While previous reports established mechanisms by which IFN-β can reduce
angiogenesis and chemotaxis toward a VEGF-enriched environment, these
mechanisms were indirect (Hallene et al., 2006; K. J. Kim et al., 1993; Takano et al.,
2014; Yang et al., 2003; Zeiher et al., 1995; H. Zheng et al., 2011). In contrast, we
uncovered a novel mechanism by which IFN-β directly reduces NRP-1 expression on
monocytes (Figure 13). We further demonstrate that this loss of NRP-1 correlates to
subsequent reduced monocyte chemotaxis toward a VEGF-enriched environment
(Figure 14 and 24).
Clinically, this mechanism is important to consider during fetal and neonatal
development. In the context of TORCH infections resulting in IFN-β production, this
could lead to the inhibition of NRP-1 expression on monocytes, resulting in reduced
angiogenesis and organogenesis and subsequent developmental impairments
(Crivellato, 2011; Gerhardt et al., 2004; Hallene et al., 2006; Phillips et al., 2016; Yockey
et al., 2018). IFN-β can be produced by various cell types dependent on the type and
location of infection, such as: fibroblasts, epithelial cells, NK cells, macrophages, and
dendritic cells (Scheu, Dresing, & Locksley, 2008; Swiecki & Colonna, 2011). TORCH
infections are infections capable of breaking the maternal-placental barrier that activate
an immune response that can lead to abnormal development and pregnancies (Arora et
al., 2017; Yockey & Iwasaki, 2018). When these infections pass the maternal-placental
barrier, they can come in contact with cells in the placenta and developing fetus.
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Varying immune responses can activate based on the type of the infection, leading to
the production of cytokines which cause different birth complications (Yockey & Iwasaki,
2018). Trophoblast cells, which are necessary for implantation and provide nutrients to
the embryo and develop to be part of the placenta, respond to type 1 IFNs by producing
IFN-stimulated genes which results in impaired differentiation, reduced developmental
capacity, and fetal growth (Baines et al., 2020; Rostovsky & Davis, 2015). Further,
exposure to infection by glial cells in the CNS also causes robust production of IFN-β
which can lead to brain developmental defects (Owens, Khorooshi, Wlodarczyk, &
Asgari, 2014; Yockey & Iwasaki, 2018). During pregnancy, VEGF expression is
upregulated both in placental tissue, peripheral blood, and in the mother’s serum (Ren
et al., 2014; Wheeler et al., 1999). This VEGF subsequently aids in angio- and
organogenesis which is necessary for fetal development and the health of the
pregnancy (Wheeler et al., 1999). Our data suggest that IFN-β produced in response to
TORCH infections will lead to the reduction of monocytic NRP-1 in the fetus, thus
resulting in reduced chemotaxis towards this special VEGF-enriched environment and
lead to subsequent reduction in angiogenesis, organogenesis, and placental health.
This model will need to be tested in vivo.
In contrast, IFN-β has recently been established as a promising treatment used
to inhibit vascularization and angiogenesis in tumor microenvironments, particularly in
the brain (Takano et al., 2014). In these previous studies, researchers have found that
presence of monocytes and macrophages at the sites of these tumors leads to poor
prognosis (Cao et al., 2001; Caponegro et al., 2018; Takano et al., 2014). Our data
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suggest that IFN-β-mediated reduction of NRP-1 may lead to reduced monocyte and
macrophage chemotaxis to the VEGF+ tumor microenvironment, aiding in reducing
angiogenesis at the site of the tumor. These possibilities require further investigations
with in vivo models.

Figure 24. Proposed IFN-β-Mediated NRP-1 Downregulation Model.
Diagram depicting that without IFN-β, monocytes express NRP-1 and are able to
migrate towards a VEGF enriched environment. In contrast, the presence of IFN-β
reduces NRP-1 expression and the monocytes no longer migrate towards VEGF.
The Suppressive Effect of Calcitriol on T Cells
It is well known that calcitriol can upregulate Tregs, protect against autoimmunity,
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and alleviate autoimmune symptoms (Jeffery et al., 2009; Lemire & Archer, 1991)
(Shaygannejad et al., 2012; Wingerchuk et al., 2005). We further showed that calcitriol
can also upregulate BiT induction (Figure 11). However, the mechanism by which
calcitriol alters naïve T cells to promote this suppressive environment is not well
understood.
In this work, we demonstrated that calcitriol promotes co-expression of surface
CTLA-4 and PD-L1. Further, total CTLA-4 is increased, consistent with previous
literature (Figure 18) (Jeffery et al., 2009; Jeffery et al., 2015). CTLA-4 is known to have
both intrinsic and extrinsic effects, where it can suppress the cell in which it is activated
on and also suppress neighboring cells by both the power of its signal and by
transendocytosis (Jain et al., 2010; Wang et al., 2012). Our data show that CTLA-4 has
an intrinsic effect on calcitriol-treated T cells (Figure 20). In line with testing the extrinsic
effect of CTLA-4, another team reported that calcitriol treated cells do perform
transendocytosis (Jeffery et al., 2015). Further, we and others reported that calcitrioltreated cells are suppressive of responder T cells, similar to tTregs (Figure 20) (Jeffery
et al., 2009). However, testing whether that suppression is dependent on CTLA-4 is a
difficulty in the field. In classic Treg studies, there are an abundance of conflicting
reports on the functionality of CTLA-4 in suppression and there is a wide variation in
culture setup and anti-CTLA-4 blocking antibody function (Walker, 2013). One such
difficulty is that suppression assays take days and CTLA-4 is rapidly recycled,
produced, and degraded which means that originally blocked CTLA-4 may no longer be
present, and the blocking antibodies can get degraded with it. In our preliminary studies,
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one donor showed CTLA-4 dependent suppression, while another did not. Further
testing will have to be performed to answer whether suppression is CTLA-4 dependent.
Calcitriol-Treated T Cells Express a Unique Cytokine Profile
While it is known that calcitriol can promote immune suppression, it was
unknown whether calcitriol is a differentiating factor for naïve CD4 T cells. Literature
reports that calcitriol leads to an increased repertoire of Th2 cells and Tregs, with a
resulting decrease in Th1 cells (Cantorna et al., 2008; Daniel et al., 2008; Jeffery et al.,
2009). However, differentiation from naïve cells or in purified cultures had not been
performed. Our data demonstrate that calcitriol does indeed reduce Th1 cytokine
production (IFN-γ) and promotes Th2 cytokine production (IL-13) (Figure 16). However,
there was no significant difference in IL-10 production (Treg) or IL-5 (Th2) and there
was no detectable level of IL-4 production (Th2) (Figure 16 and data not shown). In
contrast, there was also a significant increase in IL-6 and M-CSF production (Figure
16). M-CSF is known to shift monocytes to differentiate into the immune-suppressive
M2 macrophage phenotype. This suggests that calcitriol promotes M-CSF production by
T cells which could in turn boost immune suppression through M2 macrophage
differentiation. Further, IL-6 is not considered as a T cell cytokine under healthy
conditions, however, one group has described IL-6 producing T cells from mitogen
stimulated PBMCs, that they termed Th6 (Azizi-Semrad et al., 2010; Willheim et al.,
1999). These data suggest to us that calcitriol can promote Th6 differentiation, but
further studies will need to be performed to determine their function. Th6 function is still
unknown, because prior to this study Th6 was only found in total PBMC cultures and no
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differentiating factor was known, making it impossible to isolate. With the discovery that
calcitriol can promote IL-6 production from naïve CD4 T cells, more work is required
elucidate their immunological role.
Implications of these Data: Calcitriol Promotes Immune Suppression Through
Upregulation of CTLA-4
The evidence that calcitriol promotes checkpoint molecules CTLA-4 and PD-L1,
has the functional capacity to suppress neighboring cells, and CTLA-4 has intrinsic
suppressive functionality supports the correlation that calcitriol protects against
autoimmunity and alleviates autoimmune severity (Figures 18-20) (Jeffery et al., 2009;
Lemire & Archer, 1991) (Shaygannejad et al., 2012; Wingerchuk et al., 2005). In
contrast, these data suggest that calcitriol treatment during cancer treatment could be
detrimental, since calcitriol promotes CTLA-4 and PD-L1 expression, which are two
signaling pathways commonly co-inhibited as a cancer therapy (Wei et al., 2019). More
studies will have to be performed to better understand the role of calcitriol in the context
of cancer, and whether these markers get upregulated in a tumor microenvironment in
response to calcitriol.
While it has been previously reported that calcitriol can upregulate total CTLA-4,
the mechanism by which this occurs nor the surface phenotype had been elucidated
(Jeffery et al., 2009). Two previously established mechanisms for controlling CTLA-4
transcription are NFAT and cAMP (Gibson et al., 2007; J. Li et al., 2013). However,
calcitriol is known to inhibit both NFAT and cAMP pathways, suggesting to us that there
is another mechanism (Berg & Haug, 1999; Takeuchi et al., 1998). Our data show that
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calcitriol’s ability to upregulate CTLA-4 is dominant over an AhR agonist, suggesting
that AhR may play a role in CTLA-4 control (Figure 21 and 25). However, upon
transfection with siRNA against AhR or a scrambled control, we were unable to restore
surface CTLA-4 expression meaning we could not measure the effect of AhR on CTLA4. Further studies will need to be performed, potentially using a CRISPR/Cas9 system
to further elucidate this mechanism. However, calcitriol may be able to directly promote
CTLA-4 transcription, determined by the presence of six VDRE binding elements
upstream of the transcription start site on the CTLA-4 promoter (Figure 22 and 25). We
plan to design luciferase assays testing these VDRE sites in order to test this
hypothesis in the future.

Figure 25. Proposed Model for Calcitriol and AhR Control of CTLA-4.
Diagram depicting the proposed model of AhR inhibiting and calcitriol promoting CTLA4 transcription, leading to altered CTLA-4 on the surface of the T cell.
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